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Abstract
Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease

By
Erin Stokes
Advisor: Dr. David Calhoun

Fabry disease is an X-linked lysosomal storage disorder caused by the deficiency of the
enzyme, α-galactosidase A, which results in the accumulation of the lipid substrate. This
accumulation results in obstruction of blood flow in patients and early demise at approximately
40-60 years of age. There is currently only one FDA approved treatment (Fabrazyme) classified
as an enzyme replacement therapy. However, approximately 88% of patients experience a
severe immune response that, rarely, can be fatal and is a huge cost burden at average $250,000 a
year per patient. The structure of α-galactosidase A has been previously determined to be a
homodimer with six N-linked glycosylation sites, and the catalytic mechanism determined to be
a ping-pong bi-bi with the second substrate being water. The purpose of this research is twofold:
first, to generate a more efficient enzyme replacement therapy alternative; and second, to
develop an alternative assay to detect the activity of the enzyme that can lead to a better screen
for the presence of lysosomal storage disorders in patients. A more efficient therapy was
investigated utilizing two different host expression systems, Escherichia coli and Pichia
pastoris, as well as site directed mutagenesis of the human enzyme. Detectable expression was
not observed in E. coli, so mutagenesis was carried out using P. pastoris. Three locations on the
structure of α-galactosidase A protein were targeted for mutation the active site, the dimer
interface, and the hydrophobic loop between the active site and the third glycosylation site.
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Viable candidates for further study into a therapeutic α-galactosidase A were determined based
on catalytic efficiency (kcat/Km), thermostability, and possible glycosylation independence.
Three mutations were identified to be of potential therapeutic significance in each one of the
targeted areas. A continuous enzyme assay was developed with an artificial fluorescent
substrate, 4-methylumbelliferyl-α-D-galactopyranoside, that at acidic pH generates the same
kinetic values as the preexisting discontinuous time point assay at basic pH. This development
has not only potential laboratory benefits if implemented; it also has a clinical significance in
screening for Fabry disease and can potentially be extended to other lysosomal storage disorders.
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Chapter 1 Introduction
Fabry Disease is a rare X-linked genetic lipid storage disorder caused by an absence or
deficiency of the enzyme α-galactosidase A (α-Gal) in humans. This enzyme is primarily
responsible for the cleavage of the terminal α-galactose from the lipid globotriaosylceramide
(Gb3) in the lysosome (5). In Fabry disease, this substrate accumulates in membranes of the
lysosome as well as in the endoplasmic reticulum, cell membrane, and the nucleus leading to a
series of membrane ring-like formations. This event leads to an increase in capillary thickness
with a distinct arteriosclerotic change, particularly apparent in the kidneys and brain, which
decreases blood flow. The heart wall thickens (cardiac hypertrophy) as well causing the patient
to experience pain and ultimately resulting in myocardial infarction, renal failure, and strokes,
leading to an early death to the patient at ages 40-60 (6). Currently only one FDA approved
treatment for Fabry disease exists (Fabrazyme), which is an enzyme replacement therapy (ERT).
This treatment involves intravenous infusions typically once every two weeks often resulting in
severe side effects and immune responses that can be fatal. This therapy is also extremely
expensive costing on average $250,000 a year per patient (7). A safer, more effective, and more
affordable therapeutic needs to be made available for patients. Mutation of human α-Gal has
the potential to result in a more effective therapeutic for patients with Fabry disease.
Fabry Disease Background and Prevalence:
Fabry disease is a disease caused by the absence or deficiency of the enzyme α-Gal,
which is the result of a mutation in the gene GLA on the X chromosome. This deficiency results
in a glycosphingolipid metabolism disorder and falls into the category of a lysosomal storage
disorder, due to the main location of the accumulation of the substrate Gb3 (5). There are over

40 different lysosomal storage disorders, with Fabry disease being the second most common (5).
Unlike many other diseases of this class, for example Tay Sachs, Fabry disease patients can be
asymptomatic in early life. The initial symptoms include chronic pain, skin lesions,
gastrointestinal disorder, and vascular deterioration. The main organs where the effects of the
accumulation are observed are the blood vessels, skin, heart, kidneys, and the nervous system.
Later in life the disease causes life threatening and eventually fatal conditions such as renal
failure, stroke, and myocardial infarction (5).
Globally the prevalence of Fabry disease was initially thought to be 1 in 40,000 to 1 in
60,000 males for the classic form of the disease, which is defined as no detectable α-Gal activity.
The disease is considered to primarily affect males; however women who are heterozygous for
the trait are not only carriers, but due to random X chromosomal inactivation can also suffer
from Fabry disease in a huge variation of mild to severe (8). A random screening of 37,104
newborns for Fabry disease in Italy indicated the prevalence in males to be 1 in 3,100 (9). The
large difference in statistics was explained as being due to the inclusion of often undiagnosed
patients with residual but low activity of α-Gal, referred to as the non-classic form of Fabry
disease (late onset) with the ratio of late onset to classical being 11 to 1 (9). A random screening
of 110,027 newborns in Taiwan discovered the incidence in males to be about 1 in 1,500 (10).
This study determined there were still significantly fewer females affected than males, with
approximately 1 in 17,000 affected, this prevalence is still a much greater incidence than was
previously thought for males (10). While lysosomal storage diseases are individually rare, the
cumulative incidence of known patients and the undetected reservoir of undiagnosed patients
with these diseases constitute a significant total incidence of disease with a large societal impact.
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Structure and Catalytic Mechanism of α-Gal:
The structure of human α-Gal determined by X-ray crystallography (Figure 2) is a
homodimer, with each subunit containing two domains in a head-to-tail configuration (2). The
catalytic site located in the N-terminal domain is in an (α/β)8 domain. The second domain
contains the C-terminus and is an 8 antiparallel β-sheet barrel. The large and small domains of
the monomer have a large interface, shielding 2,500 Å2 of surface area. The dimer has a slightly
smaller interface between the monomers only covering 2,200 Å2 of surface. There are 30
residues from each monomer in six loops involved in the interface formation of the dimer into a
concave structure. Also N-linked glycosylation sites are found on six different residues on the
surface of the protein (three per monomer) (Figure 4, 13). The catalytic mechanism of human αGal was determined in 2010 also using X-ray crystallography (1). The reaction is a ping-pong
bi-bi reaction, with the two substrates being Gb3 and water. Residues, Asp170 and Asp231,
participate in two separate nucleophilic attacks on the anomeric carbon allowing for the cleavage
of the terminal galactose (Figure 1). Although these are the only two residues participating
directly in the actual cleavage mechanism, many other residues in the active site are involved in
the process through hydrogen bonding or hydrophobic interactions, such as Trp47, Asp92,
Asp93, Tyr134, Cys142 bridged to Cys172, Lys168, Glu203, Tyr207, and Arg227 (Figure 9,
page 31). Mutations in anyone of these residues could potentially impact the efficiency of the
catalytic mechanism (1).
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Figure 1. Catalytic mechanism of α-Gal. (1)
The substrate with the terminal α-galactose enters the
catalytic site and under goes two nucleophilic attacks
in series, with water entering as a second substrate
and the remainder of the molecule leaving as the first
product.

Figure 2. Crystal structure of human αGal. (2)
a) Ribbon structure of the monomer
containing two domains and the active
site. b, c) Ribbon structure of the
dimer containing two active sites on the
interface. d) Electrostatic map of the
dimer, red is negatively charged, white
is neutral, blue is positively charged,
and green is carbohydrates.
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Current Treatments and Challenges:
Today two ERTs are available for Fabry disease. One, designated agalsidase beta
(Fabrazyme Genzyme, Cambridge, Massachusetts), is FDA approved, and is produced in
Chinese hamster ovarian cells (11). The other, agalsidase alfa (Replagal, Shire Human Genetic
Therapies, Cambridge, Massachusetts) is approved worldwide but did not receive FDA approval
for use in the US. Replagal is produced by a stably transfected human diploid fibroblast cell line
designated DRX005A (12). The amino acid sequence of these therapeutic enzymes is identical
but they differ in the pattern of glycosylation. Fabrazyme and Replagal both contain mannose-6phosphate glycosylation (2). It was previously assumed that terminal mannose-6-phosphate
glycosylation was necessary for effective therapeutic cell uptake and targeting to the lysosome,
however more recently evidence was presented that alternative uptake pathways are involved in
Fabry disease (13). The receptors megalin and sortilin account for greater uptake of α-Gal in
podocytes, clinically relevant cell lines, as opposed to fibroblasts used previously (13). Further
research identified the mannose receptor to increase uptake in endothelial cells, also disease
relevant (14). These treatments pose a huge economic burden with their costs. The average cost
in the last decade for ERT is $250,000 a year per patient (7). Treatments generated from
mammalian cell lines are severely expensive because they cost so much to produce. This same
enzyme produced in E. coli or P. pastoris would be much less expensive to produce and
therefore be more affordable, thereby reducing the economic burden for healthcare.
The clinical efficacy of Fabrazyme and Replagal has been demonstrated (8, 15, 16).
However, it has also been shown that many patients respond to ERT with an immunoglobulin G
(IgG) response. Results from clinical trials with Fabrazyme indicate that 88% of male patients
developed IgG responses to infusions (17) while clinical trials with Replagal indicate that 56% of
5

male patients have IgG responses (18). These results are not directly comparable however,
because the antibody titers were generated using different assays. The effects of these antibodies
manifest visible symptoms in patients such as chills, fever, pain, and hives (19). This response
has been shown to decrease the long-term effectiveness of the drug, based on Gb3 levels
analyzed from patients’ skin (20). Replagal, with an infusion dose of 0.2 mg/kg every other
week, was compared to Fabrazyme at both the prescribed dose of 1 mg/kg every other week, and
the same, 0.2 mg/kg every other week, dosing as Replagal, and it was observed that the adverse
effects were more correlated to dosage than type of treatment (21). Since dosage is involved in
IgG response, having a therapeutic that is more catalytically active would allow for a lower
dosage for the patient, this theoretically would cause the immune response to be less severe, if at
all.
Glycosylation is very crucial in the immunogenicity of biomolecules (4). It can either
protect or enhance an immune response depending on the protein and the carbohydrate bound to
it. This is extremely important in the design of biopharmaceuticals, because it has been shown
that heterologous glycosylation can bring about neutralizing antibodies (4) as seen in the case of
commercially available α-Gal. Normal human-type glycosylation can avoid an immune response
mostly by creating a more stable protein, which is more soluble and less likely to aggregate (22).
As stated before, the only difference between Fabrazyme and Replagal is the glycosylation
pattern and, although not conclusively, it has been observed that Replagal generates less of an
immune response than Fabrazyme (20). Therefore, it can be hypothesized that if there is no
glycosylation present on the therapeutic, it decreases the likelihood of neutralizing IgG rendering
the enzyme inactive. If the protein is mutated in such a way that it is stable without the presence
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of carbohydrates, then it will not need the glycosylation to protect the therapeutic from
immunogenicity.
Current ERT does permit α-Gal to cross the blood brain barrier, which is detrimental in
the case of Fabry disease because there are neurological symptoms that cannot be addressed with
treatment (23). However, a study of chemically treated β-glucuronidase, an ERT for
mucopolysaccharidosis VII, with sodium metaperiodate followed by a sodium borohydride
reduction to modify the glycosylation, rendered it unable to undergo uptake by the mannose-6phosphate receptor. Treatment with this modified ERT showed a decrease in the accumulated
substrate from the brain in a mouse model (24). This discovery led to the hypothesis that
glycosylation can be an obstacle in the crossing of ERT through the blood brain barrier.
Clinical trials are underway for additional ERTs such as human α-Gal produced in plants
(Moss-α-Gal) produced by Greenovation Biopharmaceuticals and pegunigalsidase alfa produced
in tobacco by Protalix. Moss-α-Gal is human α-Gal produced in moss, which results in mannoseterminated glycosylation, the same as P. pastoris, and has shown improvement in uptake in disease
relevant cells (14). Pegunigalsidase alfa is produced in tobacco, which also is mannose terminated,
and is chemically crosslinked with polyethylene glycol and has been shown to be more stable and
have increased half-life in plasma (25).
In addition to ERT, molecular chaperones such as Migalastat produced by Amicus
Therapeutics, are in late stage clinical trials. The benefit of chaperone therapy is the ability to
treat tissues that are unable to take up current ERTs such as the kidneys and brain, however the
drawback is that chaperone treatment only works for specific mutations in the GLA gene (26).
Substrate reduction therapy such as Ibiglustat (Genzyme) is another treatment currently in
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clinical trials. It is similar to Migalastat in the sense that it is a small molecule and not a biologic,
Ibiglustat, however, inhibits the production of Gb3 (27) instead of increasing the clearance of Gb3
like ERT or chaperone therapy. Earlier this year a patient received treatment with gene therapy for
Fabry disease (28), which has been under consideration in the past(29).

Glycosylation
Human α-Gal has six sites of N-linked glycosylation (22). Each monomer contains three
glycosylation sites: Asn139, Asn192, and Asn215. One distinctive thing about human α-Gal, as
opposed to some of the orthologs, is that glycosylation is required for solubility in the natural
form. Asn215 must be glycosylated for the protein to be soluble in an aqueous solution.
Although Asn192 improves the secretion of the enzyme, the other glycosylation sites are not
absolutely necessary for solubility (2, 3). The removal of glycosylation at sites Asn139 and
Asn192 decrease the activity of the enzyme, but it has been previously reported to contain more
than 70% of the original activity (3). Asn215 is located near the entrance of the active site, with
a hydrophobic loop in between Asn215 and residue Tyr207, an active site residue (Figure 4).
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Figure 4. Three dimensional structure of the location of the hydrophobic
loop.
The magenta portion is Met208 to Phe211, the cyan is the rest of the
protein, and the red are the carbohydrates. The structure is 3HG4 from
PDB(1).

Tyr207

Asn215

Figure 3. Hydrophobicity map of primary sequence near Asn215(3).
Asn215 is located at position 21 (circled), Tyr207 is located at position 13 (circled) and
all residues before, are either in the active site or buried. Met208 (14) to Phe211 (17) is
in a surface exposed loop.
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Homology
Human α-Gal does not possess the theoretical maximal possible catalytic efficiency based
on diffusion limited reactions. The average literature values for the Vmax and Km of human α-Gal
are 3.4 mmoles/hr per mg and 2.4 mM respectively, which through a series of calculation shown
below, results in a turnover number (kcat) of 85 s-1 and a specific constant (kcat /Km) of 3.54x104
M-1s-1.
𝑚𝑚𝑜𝑙𝑝𝑟𝑜𝑑𝑢𝑐𝑡

3.4 𝑚𝑔

𝑝𝑟𝑜𝑡𝑒𝑖𝑛

1ℎ𝑟

1𝑚𝑜𝑙

𝑝𝑟𝑜𝑑𝑢𝑐𝑡
𝑥
𝑥
ℎ𝑟 3600𝑠 1000𝑚𝑚𝑜𝑙

𝑝𝑟𝑜𝑑𝑢𝑐𝑡

𝑥

1000𝑚𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛
1𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛

𝑥

90000𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛
1𝑚𝑜𝑙𝑝𝑟𝑜𝑡𝑒𝑖𝑛

= 85𝑠 −1

1

The molecular weight of the human α-Gal native dimer is approximately 90 kDa. The average
values for Vmax and Km were determined from the table of literature values of human α-Gal from
a compilation of sources(30). The optimum diffusion controlled efficiency of an enzyme is a
specific constant (Kcat/Km) in the range of 108 to 109 M-1s-1, indicating that there is an apparent
possibility for improvement in catalytic properties for the normal human α-Gal.
The literature contains kinetic data on α-Gal homologs (31) that have greater catalytic
efficiency (Kcat/Km) compared to the human enzyme (Table 2). This further illustrates that the
human enzyme has a capacity to have a greater intrinsic catalytic activity.
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Table 2. Comparison of the activity of homologs to human α-Gal (30).

kcat/Km Relative BLAST
PubMed
Colloquial Km Kcat
-1
-1 -1
Accession code Genus and species Name
(mM) (s ) (M s ) kcat/Km %Identity
NP 000160

Homo sapiens

Human

6.88

37.8

5490

1

100

NP 038491

Mus musculus

Mouse

1.4

N/A

N/A

N/A

78

1.8

30.1

16700

3

28

0.65

23.3

35800

6

39

4.5

286

63600

12

33

0.81

61.9

76400

14

46

0.198

272

1370000

250

37

WP
004844583.1
AAC99325
P41947
BAB83765
AAG24511

Ruminococcus
gnavus
Bacteria
Saccharopolyspora
erythraea
Bacteria
Saccharomyces
cerevisiae
Yeast
Clostridium josuil
(Catalytic Domain) Bacteria
Phanerochaete
chrysosporium
Fungus
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Expression in Pichia pastoris
P. pastoris is a methylotrophic yeast strain that has been successfully been utilized to
express functional human α-Gal in this lab (32). A P. pastoris expression vector, pPICZαA, is
commercially available from Invitrogen that uses the alcohol oxidase (AOX) promoter to produce
the target protein as well as a Zeocin resistance gene for selection. This vector can be linearized
and integrated into the genome of P. pastoris in the AOX gene. The strain can then use methanol
as a metabolite and express human α-Gal.
Site Directed Mutagenesis
Often, site specific mutation is used to explore the effect one residue has on a specific
function and is a much more focused and targeted approach (33). My research focuses on three
specific enzyme locations in α-Gal to implement mutations: the catalytic site, the dimer interface,
and the glycosylation sites. The catalytic site was investigated to directly increase the activity of
the enzyme, by introducing mutations that are observed in homologous enzymes with greater
activity (Table 2). The dimer interface was explored to evaluate the importance of the stability
of the dimer in maintaining activity. The third glycosylation site (Asn215), particularly the
residues surrounding it, was selected for mutation to test the hypothesis that it may be possible
stabilize a glycosylation deficient mutant at the third glycosylation site.
Important Therapeutic Properties
A successful candidate for a therapeutic would contain an increase in one, if not more of
the following three criteria: kinetic activity, stability, and glycosylation independence. An
increase in activity is defined as an increase in the efficiency (kcat/Km) of the enzyme and would
need to be observed with either greater or equal stability as the wild type. An increase in thermal
stability is experimentally defined as the greater retention of activity after exposure to increased
12

temperatures. This increase in stability also needs to be observed with at least the same catalytic
efficiency as the wild type enzyme. Glycosylation independence must not compromise either the
catalytic efficiency or the stability of the enzyme as compared to the wild type. A summary of
the mutants constructed for this research divided by location of mutation is displayed in Tables
3-5.
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Table 3. Summary of Active Site Mutants
Purification
Method

Mutation
Y207W
E203C
E203C/Y207W
E203N
E203C/W204C/P205X/
L206X/Y207W
E203C/W204N/P205X/
L206X/Y207W

Rational

Image

DEAE/SP
Homology

Not purified
Organic
Chemistry
Principles

D170C

Table 4. Summary of Interface Mutants
Mutation
F273C
W277C
F273G/W277G
F273G
W277G
F273C/W277C

Purification
Method
DEAE/SP
DEAE/Thiogal
SP

Rational

Image

Thiol/aromatic
stabilization
Disrupt dimer

Not Purified

F273C/N278C

Disulfide linkage
of dimer

Table 5. Summary of 3rd Glycosylation Site Mutants
Mutation
M208E/N215Q
M208E/F211H/
N215Q
F211H/N215Q
M208X/N215Q
W209X/N215Q
F211X/N215Q
N215Q
M208E

Purification
Method
DEAE/Thio-gal
DEAE/SP
Not Purified

DEAE/SP

DEAE/Thio-gal

Rational

Image

Zebrafish
Homology

Deletion
Homology
Glycosylation
Knockout
Follow up
M208E/N215Q
results
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Chapter 2 Expression of Human α-Gal in E. coli
Overview
This research attempted to conduct mutagenesis experiments in E. coli. In order to
accomplish this, expression plasmids of wild type α-Gal were constructed as well as an
expression strain. E. coli was investigated initially because of its ease of selection, its cost
efficiency, and its inability to glycosylate proteins.
E. coli Expression Strains
E. coli contains an endogenous α-Gal so the gene must be inactivated in order to screen
for the human enzyme in its presence. Deletion of α-Gal gene, melA, renders E. coli incapable
of growth on melibiose or the formation of a blue precipitate from 5-bromo-4-chloro-3-indolyl αD-galactopyranoside (X-Gal). Human α-Gal contains several disulfide bonds located throughout
the enzyme including in the active site. Wild type E. coli does not have the catalytic mechanism
for the formation of disulfide bonds in the cytoplasm due to the presence of several
thioreductases. The expression strain therefore should have mutations that allow for proper
folding of α-Gal. Two specific enzymes were characterized, glutathione reductase (gor) and
thioredoxin reductase (trxB), that when deleted, result in proper folding of some human enzymes
in the cytoplasm of E. coli (34). These types of strains are commercially available; however all
of them contain their own endogenous α-Gal. The codons for E. coli translation and humans are
not the same in all cases, which often makes expression of human proteins in an E. coli host
potentially inefficient. Human α-Gal contains many codons rarely found in E. coli, so to enable
expression a plasmid containing 7 tRNAs for human codons was obtained (pRARE).
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E. coli Expression Vector
The cDNA of human α-Gal was determined and contained in a plasmid from previous
research in this lab (35). This cDNA was integrated into two different pET expression vectors
(Novagen) which are widely used expression vectors for E. coli, one targeting the periplasm
(pET-20b) and the other targeting the cytoplasm (pET-14b). Both plasmids contained an
ampicillin (amp) resistance gene for selection purposes. The vector maps for both plasmids are
shown in Figures 5 and 6. These vectors were evaluated to determine if they were capable of
producing sufficient α-Gal to have melA knockout E. coli sustain growth on melibiose.
Methods and Materials
Construction of the Expression Vectors
Two different vectors were designed to express human α-Gal: one for the expression in
the periplasm (pET-20b vector) and one for the expression in the cytoplasm (pET-14b vector).
The pET expression vectors underwent a double restriction digestion to linearize the plasmids:
pET-20b was digested with NcoI and EcoRI, and pET-14b was digested with NcoI and XhoI.
The vector maps for both plasmids are displayed in Figures 5-6. Both plasmids were then
purified using 1% agarose electrophoresis to remove the small fragment.
The α-Gal cDNA, contained in pCC106 (32), was isolated using a plasmid preparation
with a GeneJET kit. The α-Gal cDNA was amplified using CloneAmp™ HiFi PCR Premix
with primers that contained a 15 bp homology with the respective expression vector and an
approximately 20 bp homology with the α-Gal cDNA. In the case of pET-20b a one bp
mismatch (A to C) was designed in the 5’ primer to convert a vector-encoded Met to Leu, the
codon faithful to the N-terminal sequence of the mature form of human α-Gal. In the case of
pET-14b, the 5’ primer contains an additional two nucleotides (GC) that are in neither the vector,
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nor in the cDNA of α-Gal. These two nucleotides complete the codon GGC that codes for an
Ala, therefore, a frame shift mutation does not result. The resultant α-Gal will contain an
additional two residues (Met and Ala) on the N-terminus; the Met is necessary to ensure
translation and the Ala is included because a Met-Leu peptide is almost never posttranslationally
cleaved and is rapidly targeted for degradation by the cell(36). Met-Ala is cleaved much more
frequently and has a longer half-life (37). Ala is also often cleaved from the N-terminus by heat
shock protein 31, which demonstrates peptidase activity for N-terminal Ala and Gly(38). The
sequence of the amplification primers is displayed in Table 6.
The amplified insert was purified using spin column purification, and was then combined
with the vector using the In-fusion HD cloning kit (Clontech), which uses homologous
recombination to integrate the insert into the vector(39). These vectors were drop dialyzed and

Primer
pET-20b 5’
pET-20b 3’
pET-14b 5’
pET-14b 3’

Table 6. PCR primers for ligation of wild type α-Gal.
Sequence
CAGCCGGCGATGGCCCTGGACAATGGATTGGCAAG
GACGGAGCTCGAATTTTAAAGTAAGTCTTTTAATG
AGGAGATATACCATGGCCCTGGACAATGGATTGGCA
CAGCCGGATCCTCGAGTTAAAGTAAGTCTTTTAATG

transformed into the generated expression strain (see generation of expression strains section)
and screened using ampicillin (Amp) because both pET vectors contain an Amp resistance gene.
Transformation was performed using electroporation with a Gene Pulser with procedure for
electrocompetent cells (32). Plasmids were isolated from cultured transformants using the same
GeneJet kit. The resultant vectors were visualized using 1% agarose electrophoresis for the
presence of the insert and then sequenced by Genewiz and verified by alignment to the vector
and the α-Gal sequence using Serial Cloner.
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Figure 5. pET-14b expression vector map and cloning region (Novagen)
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Figure 6. pET-20b expression vector map and cloning region (Novagen)

19

Construction of the Expression Strain
Three strains containing the desired mutations for the expression of α-Gal were acquired:
one was purchased from New England Biolabs, Shuffle, containing deletions in both the gor and
trxB genes, another from the E. coli stock center, JW4080-3, and the third was purchased from
Novagen, Rosetta, containing the pRARE plasmid. JW4080-3 is a melA knockout strain in
which melA was interrupted by the insertion of a kanamycin (Kan) resistant gene(40). This Kan
insertion was moved from the JW4080-3 strain and using homologous recombination, inserted
itself in the melA gene of the commercially available gor/trxB knock out strain (Shuffle) using
phage P1vir transduction. JW4080-3 was infected with phage P1vir to create a lysate. After
infection, phage P1vir integrates fragments of the chromosomal DNA of the host at random upon
lysis. Infection of a new strain with these phages will contain either the random fragment of the
previous strain’s chromosome or the viral DNA. The Shuffle strain was transduced using the
lysate from JW4080-3 and the resultant mixture was plated on Luria Broth (LB) plus Kan to
screen the colonies that have gained the Kan resistance insertion, which likely knocked out
Shuffle’s melA, from methods illustrated in the Cold Spring Harbor Advanced Bacterial
Genetics Manual(41). Since the melA knock out was generated with a Kan resistance gene and
the gor/trxB strain is Kan sensitive, screening on plates containing Kan selected only mutants
that retrieved this fragment of the chromosome. These colonies were then patched on to M9
melibiose plates, to confirm the deletion of the melA gene. After the phenotype was confirmed
the pRARE plasmid was inserted using electroporation (32).
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Detection Methods for α-Gal
Plate Assays
The transformants with the confirmed α-Gal sequence were patched on an agarose plate
containing M9 media with melibiose as the carbon source, as well as an LB low salt plate
containing X-Gal, which causes a blue product to be visible upon cleavage with α-Gal(32). Both
expression plates were at acidic pH (4.5) to enable the catalysis of human α-Gal. The expression
of α-Gal in the pET vector is under the control of the bacteriophage T7 transcription promoter
that is induced with isopropyl β-D-1-thiogalactopyranoside (IPTG). IPTG was spread on the
plates to a final concentration of 0.4 mM, allowed to dry prior to plating, and incubated for two
days at 35oC. This incubation temperature was chosen due to the temperature sensitivity of the
melB gene in E. coli that codes for a melibiose transporter protein, which is much less efficient at
37o C (42). Melibiose is also transported into the cell via the lactose transporter protein, which
operates at 37oC, however growth at 35o C enables the use of both systems (43). Growth on M9
with melibiose as well as the presence of the blue product ensures the presence of functional
human α-Gal.
Whole Cell Enzyme Assays
The most quantifiable method to determine the activity of α-Gal is by enzyme assay
using 4-methylumbelliferyl-α-D-galactopyranoside (MUG), a synthetic substrate that after
excitation at 365 nm results in a fluorescent product that can be measured at a wavelength of 450
nm. Activity was measured in units, where one unit is defined as the amount of enzyme required
to convert 1 nmole of MUG to 4-methylumbelliferone (MU) in one hour at 37oC (32). This
method is illustrated in Ioannou’s dissertation for whole cells using human enzyme(44). In the
studies involving E. coli enzyme, the same procedure was used with optimized assay buffer
21

conditions for E. coli’s endogenous α-Gal (45). Enzyme in solution can also be assayed using
MUG (32).

Results
Construction of human α-Gal Expression Vectors:
The stepwise construction of the expression vectors was analyzed in silico using Serial
Cloner. The pET vectors were double digested, pET-20b with NcoI and EcoRI and pET-14b
with NcoI and XhoI, and visualized and purified using 1% agarose electrophoresis as seen in
Figure 7-a and b. The α-Gal sequence was amplified from a previously utilized plasmid with the
primers illustrated in Table 6 using PCR. The PCR product was also visualized using 1%
agarose electrophoresis with a 2 kb reference control band as seen in Figure 7-c. This amplified
product and the digested vector were combined as stated in the In-fusion protocol for
recombination into the plasmid. These plasmids were drop dialyzed and electroporated into the
constructed strain and selected on LB low salt with 50 µg/mL Amp. The colonies were then
inoculated into LB low salt with 50 µg/mL Amp in a liquid culture and isolated using a GeneJET
plasmid prep kit. The plasmid was then digested and ran using 1% agarose electrophoresis to
verify the presence of the insert (Figure 7-d and e) and then sent out for sequencing with
universal T7 primers. Genewiz returned an intact α-Gal sequence located directly after the
periplasmic signaling peptide in pET-20b and after the Met-Ala in pET-14b that was aligned
using Serial Cloner.
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a)

b)
2 kb
insert

a-Gal 20

a-Gal 14

1.5 kb
1 kb

c)

pET-14 pET-14 pET-14 pET-14
-Gal -Gal uncut
cut
uncut cut

d)

e)

Figure 7. 1% agarose electrophoresis illustrating (a,b) successful double digestion of pET-14
and pET-20 c) successful amplification of α-Gal. d, e) α-Gal pET-20b and α-Gal pET-14b
plasmids isolated from transformants and digested with Hind III to demonstrate the increase in
size due to the insertion of α-Gal.
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Construction and evaluation of E. coli expression strain
Transduction using phage P1vir was used to insert a kanamycin (Kan) resistance
transposon integrated in the melA gene (gene that codes for E. coli α-Gal) from strain JW4080-3
into the commercially available strain Shuffle (C3028H) purchased from New England Biolabs
containing the mutations ΔtrxB (thioreductase), Δgor (thioreductase), Δlon (protease), ΔOmpT
(protease), and T7 polymerase (CC1017). The T7 polymerase is used for transcription of the
human α-Gal gene incorporated in the pET expression vector constructed previously with
ampicillin (Amp) resistance. The strain also contains a compatible pRARE plasmid isolated
from the Rosetta strain purchased from Novagen that contains tRNA for 7 rare codons in E. coli
but common in humans. This plasmid contains a gene for chloramphenicol (Cam) resistance.
The strains containing a plasmid encoding the cDNA of human α-Gal failed to grow on
melibiose indicating no detectable expression. The results of construction and expression of
these strains are summarized in Figure 8.
E. coli strain (CSR603) (with an intact melA gene) was grown in liquid culture to
determine if MUG and/or /MU could be transported to and from the cytoplasm and be detected
using whole cell assays. Table 7 displays these results indicating that whole cell assays are a
viable method of detection of α-Gal activity. Therefore, the constructed strains were also grown
in culture and evaluated for human α-Gal expression. The whole cell assay results were in
agreement with the plate assay results and also did not result in detectable human α-Gal activity.
Thus, efforts were initiated to use P. pastoris to monitor α-Gal activity and mutant analysis.
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Table 7. Enzyme activity measured in whole cells for E. coli α-Gal.
Conditions

CSR603 grown in M9 melibiose
assayed at pH 4.5
CSR603 grown in LB low salt
assayed at pH 4.5
CSR603 grown in M9 melibiose
assayed at pH 7.5
CSR603 grown in LB low salt
assayed at pH 7.5

Activity
(U/mL/µL
cells)
0
0
350
40

25

Day 1

LB+ 34 µg/mL Cam

LB+50 µg/mL Kan

LB+ 100 µg/mL Amp

LB
Day 5

M9 melibiose pH 4.5+IPTG
Patch Number
Host Strain
1
2
3
4
5
6
7
8

Shuffle
CC1017
Rosetta
CC1018
CC1019
CC1020
CC1021
CC1024

9

CC1025

10

CC1026

11

CC1027

M9 melibiose pH 7+IPTG
Plasmid (s)
melA
pRARE
pET-20
pET-14
pCC307
pCC308
pET-20 and
pRARE
pET-14 and
pRARE
pCC307 and
pRARE
pCC308 and
pRARE

M9 glucose pH 4.5
Human α-Gal
Antibiotic
resistance

+
Δ
+
Δ
Δ
Δ
Δ
Δ

+
+
-

Δ

-

Δ

+

Δ

+

Kan
Cam
Kan and Amp
Kan and Amp
Kan and Amp
Kan and Amp
Kan, Amp, and
Cam
Kan, Amp, and
Cam
Kan, Amp, and
Cam
Kan, Amp, and
Cam

Figure 8. Patching for expression of human α-Gal.
Patches 1-3 contain the control strains, which are the origin of the expression strains. Patches 4-7 are all
strain CC1017 derivatives with the respective plasmid. Patches 8-11 are the expression strains containing
the pRARE plasmid. It is observed that only the host and the pRARE transformants grow on Cam. Only
strains derived from CC1017 grow on Kan and only strains containing pET derived plasmids grow on
Amp. Only melA+ strains grow on melibiose, no strain containing a plasmid for human α-Gal grew on
melibiose.
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Discussion
Functional human α-Gal could not be detected in E. coli despite the location of
expression (periplasm versus cytoplasm), human tRNA codons, or the ability to produce
disulfide bonds. We hypothesize that α-Gal was produced but was extremely unstable
unglycosylated so it was rapidly degraded before it could be detected. The constructed strain
grew very slowly, even pre-induction, making it less ideal for production of proteins as well.

In

January of 2015 Unzueta et al. reported that they were unable to produce functional human α-Gal
in E. coli as well (46). That lab applied all the same techniques utilized here, as well as
additional techniques, and they were still unable to produce detectable α-Gal in E. coli. For these
reasons mutagenesis and production was moved to P. pastoris, which is capable of glycosylation,
secretion, growth at high densities, and is still more cost efficient to produce than mammalian
cells.
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Chapter 3 Site directed mutagenesis of human α-Gal in P. pastoris
Overview
Three locations were investigated for potential therapeutic improvement to α-Gal: the
active site; the dimer interface; and the surrounding region of the third glycosylation site. The
blue/white screen offers an accurate but qualitative analysis of each mutant’s respective activity.
As such there is no certainty that the activity observed is a result of a more/less efficient enzyme
or due to more/less abundance of production. Also in the case of increase of efficiency, there is
no way to determine if this is a result of an increase in binding affinity of the substrate (Km),
catalytic activity (Vmax), or even an increase of stability. To address these issues, all the interface
mutants as well as the mutants giving a positive/blue result in the initial screening were subjected
to further screening. This involved culturing in shake flasks, purification, thermostability
analysis and kinetic analysis identifying the parameters (Km, Vmax, and kcat). The kinetic analysis
was conducted using a newly developed continuous assay using the artificial substrate MUG,
discussed in depth in Chapter 4. In the case of one of the interface mutants, the quaternary
structure was evaluated using size exclusion chromatography and native PAGE. The most
promising of these mutants were then selected for scaled up production in a bioreactor, followed
by purification and in depth analysis.
Active Site Mutants
The active site was selected to potentially increase catalysis. Active site mutations were
identified using homology modeling using published values for homologs with increased kinetic
efficiency compared to the human. Table 2 (Chapter 1) contains the species that were chosen for
comparison to human α-Gal and their kinetic data. Only the crystal structure for α-Gal from
humans and S. cerevisiae were previously determined (47). Active sites for the other homologs
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were determined using homology modeling with the program Protein Homology /
analogY Recognition Engine (PHYRE) as well as primary sequence analysis using
ClustalOmega. These structures were then compared to human α-Gal using PyMOL to identify
the residues in the active site. Figure 9 (a) indicates the active site for human α-Gal and Figure 9
(b) indicates the residues that were determined to be different in the respective homologs. R.
gnavus was excluded from the Table because the predicted structure varied greatly from that of
the human enzyme. M. musculus was also excluded because the active site is predicted to be
identical to that of the human enzyme.
It was also observed that in addition to the residues Glu203 to Cys203 (E203C) and
Tyr207 to Trp207 (Y207W) being different in the homologs, that the secondary structure at that
location in the active site was also altered as well. In the human enzyme the primary sequence
containing those two active site residues is EWPLY, and the secondary structure is an alpha
helix. In the studied homologs, this same region is a disordered loop containing the residues
CCW (C. josuil) or CNW (S. cerevisiae and P. chrysosporium). These mutations were
constructed to also determine if this predicted secondary structure change resulted in an
alteration of activity.
An additional active site mutation was considered, Asp170 to Cys170 (D170C), which is
the first of two Asp residues that are directly involved in the catalytic mechanism. Human
residue D170 is responsible for the initial nucleophilic attack on the anomeric carbon of
galactose (1). A mutation of this residue to a Cys was selected because it was hypothesized
(Kevin Ryan, personal communication) that a thiol would act as a better nucleophile than a
hydroxyl, ultimately increasing the rate of the initial step. The PHYRE program was used to
predict the 3 dimensional structure of human α-Gal with the active site mutations E203C and
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Y207W displayed in Figure 10, D170C (Figure 11). These predictions were carried out to
determine if there was a predicted adverse structure change with the implementation of these
mutations.
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Figure 9. a) ChemDraw image of human α-Gal active site bound to the
product galactose. The blue dotted lines represent hydrophobic
interactions and the red lines represent hydrogen bonds. b) Table of
homologs comparing the relative efficiency to different residues present
in the active site. The number system is based on the human α-Gal.
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Figure 10. Superimposition of wild type human α-Gal (1)
with the projected structure of the mutant E203C/Y207W
from PHYRE. Image generated using PyMOL.

Figure 11. Superimposition of wild type human α-Gal (1)
with the projected structure of the mutant D170C from
PHYRE. Image generated using PyMOL.
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Interface Mutations
The interface was selected to evaluate the importance of the dimer to the stability of the
enzyme. A covalently polyethylene glycol linked dimer is in clinical trials that has an increased
of stability of the enzyme (25). Two residues were identified in the dimer interface, Phe273
(F273) and Trp277 (W277) that were predicted to participate in the formation of the α-Gal
homodimer. It has previously been claimed (48) that a mutation in both of these residues to a
Gly results in a monomeric species that is still functional catalytically. The benefit of a
potentially monomeric therapeutic is the prospective uptake into podocytes (kidney cells) in vivo,
which the current therapeutics are unable to achieve(48). This research explored the possibility
of a disulfide linked dimer through a mutation of the previously identified residues to Cys and
comparing that to the monomer (Gly) as well as the wild type enzyme. It has previously been
reported that a thiol/aromatic interaction has the ability to stabilize proteins(31) so single Cys
mutants were constructed as well (F273C and W277C). Another potential disulfide bound
mutation was identified using the program MOdelling of Disulfide bond In Proteins (MODIP) at
Phe273Cys/Asn278Cys (F273C/N278C). PHYRE was again used to predict the 3 dimensional
structure of human α-Gal with the interface mutations F273C and W277C displayed in Figure
12A, F273G and W277G in Figure 12C, and Swiss-Model was used for F273C and N278C in
Figure 12B.
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A)

B)

Figure 12. A) Superimposition of wild type
human α-Gal (1) with the projected structure of
the mutant F273C/W277C form PHYRE. Image
generated using PyMOL. B) Projected structure
of the mutant F273C/N278C from Swiss-Model.
Image generated using PYMOL. C)
Superimposition of wild type human α-Gal (1)
with the projected structure of the mutant
F273G/W277G form PHYRE.
C)
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Third Glycosylation Site Mutants
The human α-Gal has three N-linked glycosylation sites per monomer (Figure 13). Site
three (N215), was shown to be the most important for retaining activity and stability of the
enzyme (3). Upon the subsequent determination of the crystal structure of the human α-Gal it
was observed that there is a hydrophobic loop that extends from the active site (Y207) to the
third glycosylation site (N215). We hypothesize that the glycosylation is necessary at this site to
shield this hydrophobic loop from the surrounding aqueous solution. In order to develop a
potentially glycosylation independent therapeutic that theoretically could decrease an immune
response or increase blood brain barrier permeability (24), the hydrophobic loop was targeted for
mutagenesis. The basic local alignment search tool (BLAST) was used with the query listed
below to identify any homologs that were not glycosylated in that region. Danio rerio
(Zebrafish) was identified as a potential candidate because it lacked glycosylation site 3, also
contains hydrophilic residues near this region of the enzyme sequence, and it catalyzes the same
catalytic reaction with the natural Gb3 substrate. The residues Met208 (M208) and Phe211
(F211) were selected for mutagenesis to the gene for the zebrafish enzyme because of their
hydrophobicity. Analysis of the three-dimensional structure of the human enzyme in comparison
with the previously mentioned active site homologs also identified that the loop was much longer
in the human enzyme. The longer loop is much more surface exposed than in the homologs so it
was hypothesized that deletions of the hydrophobic residues may stabilize the enzyme. Both the
Zebrafish and the deletion mutations described are summarized in Figure 13. In order to remove
the glycosylation site, N215 was mutated to a Gln to prevent the post translational addition of the
carbohydrate because glycosylation is selective to only Asn, while retaining similar charge
properties (3). Upon analysis of the Met208Glu/Asn215Gln (M208E/N215Q) mutant a large
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increase in activity was observed, but the enzyme was not very stable. The single mutant M208E
was generated including the glycosylation site to further investigate this increase in activity.
All of the mutants explored in this research were constructed with the wild type P.
pastoris strain X-33. This strain produces high mannose glycosylation that can vary in
molecular weight from preparation to preparation and would potentially be antigenic in vivo. To
address this issue, human α-Gal was integrated into the humanized P. pastoris strain SuperMan5
for further studies outside the scope of this research. SuperMan5 is commercially available as
GlycoSwitch (Biogrammatics) and contains three genetic manipulations that result in only 5
mannose glycosylation(49). The blue/white screen of the integration of the wild type and F273C
α-Gal into the SuperMan5 strain are located in Figure 14C (Results). Other than those indicated
all other strains derive from X-33.

198 IVY SCREWPLYMWP FQKPNYT 217
IVY SCREWPLYXXP XQKPNYT
116 IVY SCREWPLYEWQ HQQPDYE 135
human)

Human primary sequence
Three residues selected for deletion (X)
Zebrafish (D. rerio)(red differ from

Figure 13. Primary sequence alignment to identify sites for mutation near glycosylation consensus
NYT (215-217).

36

Methods and Materials
Site Directed Mutagenesis
All the previously mentioned mutants were constructed using New England Biolabs’ Q5
Site Directed Mutagenesis PCR kit in a pPICZαA P. pastoris expression plasmid(32) using
custom mutagenesis primers constructed by Invitrogen (Thermo Scientific). All constructed
mutants are listed in Table 8 located in the results section. Once the plasmids were constructed
they were transformed into E. coli chemically competent cells purchased from either New
England Biolabs (C2978H) or Agilent (XL 10-Gold Ultra Competent) and selected for 25 µg/mL
Zeocin resistance. Selected transformed colonies were cultured and isolated using a GeneJet
Plasmid Miniprep kit purchased from Thermo Scientific and were sequenced by Genewiz to
identify the presence of the mutation. Sequence and alignments to the wild type α-Gal cDNA as
well as the translation of the nucleotides were evaluated using Serial Cloner.
Construction and Screening of P. pastoris Strains
Once the mutant sequence had been confirmed, the plasmids were digested with PmeI
and visualized on a 1% agarose gel. The linear plasmid was then purified by either drop dialysis
or a Gene Clean III purification kit and electroporated into electrocompenent X-33 P. pastoris
(32). The transformed strains were selected on 100 µg/mL Zeocin plates and all resultant
transformants were patched on to increasing concentrations of Zeocin (500 and 1000 µg/mL) to
identify the strains with the highest amount of vector integration into the AOX gene of the
chromosome. The higher the copy number of the integrated α-Gal genes the more α-Gal the
strain will produce. The highest copy number strains were then patched on a nitrocellulose
membrane and cultured overnight on a YPD agarose plate, then transferred to a minimal
methanol plate to turn on α-Gal expression utilizing the AOX promoter for an additional night.
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The next day the membrane was incubated in a 100 mM sodium acetate buffer containing 1
mg/mL X-Gal (diluted from 20 mg/mL dissolved in dimethyl sulfoxide) to determine if the
enzyme was functional using a blue/white screen.
Culturing P. pastoris in shake flasks and purification of human α-Gal
All mutant strains as well as the wild type were cultured as described in Chen et al (32).
In order to most accurately determine the kinetics and ultimately the stability of the mutant
enzymes, the mutants need to be pure. The culture was harvested via centrifugation and
diafiltrated using either a 50 kDa or a 10 kDa hollow fiber filter (Spectrum Labs), depending on
the anticipated molecular weight, into 10 mM sodium phosphate buffer pH 6.5. Two alternative
methods for purifying α-Gal utilizing two chromatography columns have been explored. Both
methods utilize as the first column, the anion exchange Diethylaminoethyl cellulose (DEAE)
resin (GE Healthcare) eluted in 10 mM sodium phosphate buffer pH 6.5 with a gradient of
increasing sodium chloride concentration up to 1 M (50). The first method explored pooled the
elution tubes and dialyzed them into a 25 mM citrate-phosphate buffer pH 4.8 with 0.1 M
sodium chloride and loaded it on an affinity immobilized-D-galactose gel column (Thio-Gal,
Pierce No. 20372) column (30). The pure protein was eluted utilizing a step elution into 25 mM
citrate-phosphate buffer pH 5.5 with 0.1 M galactose and 0.1 M sodium chloride. This method
was effective but the recovery was very low because approximately 2/3 of the enzyme fails to
bind to the column. It is hypothesized that varying glycoforms resulting from production in P.
pastoris bind to the resin with distinctly different affinities. Another issue is the resin binds to
the active site of the enzyme and was observed to destroy the activity of the active site mutants
when applied. For these reasons an alternative second column was investigated.
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The second method explored the α-Gal elution peak, pooled and dialyzed against 25 mM
citrate-phosphate buffer pH 4, for the second sulphopropyl (SP) Sepharose column (GE
Healthcare), a cation exchanged resin. This process was developed based on the literature
isoelectric point of human α-Gal 4.7 (51). The benefits of this purification method are the speed
at which purification can be accomplished as well as the reduction in cost as opposed to affinity
chromatography methods. This method successfully purified the active site mutant enzymes for
which it was used by analytical analysis with sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Human α-Gal produced in P. pastoris results in multiple
glycoforms of varying numbers of mannoses, which results in multiple bands observed on an
SDS-PAGE. These bands have identified as α-Gal via western blot(30) as well digestion of
glycosylation with Peptide-N-Glycosidase F resulting in a single band(32). Three of the
interface mutants F273C, F273C/N278C, and F273G/W277G were not successfully purified due
to poor stability during purification attempts and F273G/W277G’s failure to bind DEAE
columns.
Kinetic analysis of α-Gal
Substrate saturation curves using MUG were evaluated in three replicates with substrate
concentrations ranging from 0.1 mM to 2 mM using the continuous enzyme assay detailed in
Section IV. The Km, Vmax, kcat and the efficiency kcat/Km were determined using three methods:
Lineweaver-Burke for Michaelis-Menten kinetic curves; Eadie for sigmoidal curves; and nonlinear regression for all using Sigma Plot and Prism.
Thermostability evaluation of α-Gal
Each purified mutant was evaluated for thermostability by being incubated in a water
bath at 50oC. A sample was taken at varying time points and placed on ice, and all activities
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were read using the continuous assay simultaneously in comparison to the initial activity prior to
incubation. The initial activity of each respective mutant was considered to be 100% activity,
and the activity at each time point was divided by the initial activity to define the percent
activity. The incubation was carried out for two hours.
Analysis of the dimeric properties of α-Gal
It was reported that mouse α-Gal is observed to have different quaternary structure at
different pH and varying salt concentrations(52). This experiment was performed with the
human enzyme to evaluate if the same trends would be observed. Wild type human α-Gal was
evaluated using a Superdex G200 size exclusion column at pH 7.4, 6.5, and pH 5.4 in the
presence and absence of 150 mM or 100 mM sodium chloride.
Electrophoresis analysis
Briefly to perform an SDS-PAGE, protein samples were mixed with an equal volume of
reducing sample buffer (Bio-Rad Laemmli sample buffer with 5% β-mercaptoethanol) and
heated for 5 minutes at 95°C before loading on a Mini-Protean TGX Precast Gel 4–20% (w/v)
(Bio-Rad No. 456-1094). The running buffer for the SDS-PAGE was 25 mM Tris, 192 mM
glycine, and 0.1% SDS. Bands were identified by Coomassie blue staining via the modified
Fairbanks protocol(53). Native PAGE followed a similar protocol as the SDS-PAGE,
supplementing the denaturation process with native sample buffer (Bio-Rad) and the running
buffer used was the same as the SDS-PAGE minus the addition of SDS, with or without 50 mM
galactose. The gels were stained utilizing identical procedures.
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Culturing P. pastoris in a bioreactor and purification of select mutants
High-density production of human α-Gal from P. pastoris in a 7 L bioreactor was
described previously(30). The purification of the mutants was similar to the process for shake
flask, except scaled up accordingly. The differences of note are that prior to the diafiltration all
post-centrifuged harvests where filtered through 0.2 µm hallow fiber filter (Spectrum Labs, No.
M22M-300-01N), and the Y207W mutant was not pure after the SP column so it was purified
further on a Superdex G200. E203C/Y207W was successfully purified utilizing the two-column
DEAE and SP purification as was the shake flasks.
Enzyme activity and protein concentration analysis
Activity of α-Gal was assayed using the synthetic substrate, MUG as described
previously (32) with modifications to be performed in a microtiter plate. Enzyme activity is
measured in units/ml where one unit is defined as the amount of enzyme required to convert 1
nmole of MUG to MU in one hour at 37°C. An aliquot of 3 μl was added to 27 μl of 5 mM MUG
in 100 mM sodium acetate buffer, pH 4.6. This mixture was incubated at 37°C, and 10 μl
aliquots were taken at two time points; the second was twice the first, and added to 290 μl of 0.1
M diethylamine in a microtiter plate to stop the reaction. The fluorescence of each sample was
measured at an excitation wavelength of 365 nm and an emission wavelength of 465 nm using a
Tecan Infinite F200 microtiter plate reader. A standard curve of 10 μl of 0 – 0.5 nmol MU
dissolved in methanol in 290 μl of 0.1 M diethylamine was used to quantitate the fluorescence
emitted. Protein concentration was determined by measuring the absorbance at 280nm on A
NanoDropTM 2000/2000c and calculations of concentration were determined using the literature
extinction coefficient of human α-Gal(54).

41

Galactose activity assays
The wild type and the W277C mutant were evaluated for changes in activity as a result of
galactose. Parallel continuous assays were performed in triplicate containing varying
concentrations of galactose for both the wild type and the mutant. The activity at 0.5 mM
galactose was considered to be 100% activity, and the activity at each additional concentration of
galactose was divided by the initial to define the percent activity.
Results
Blue/White Screen
The X-Gal blue/white screen images for all of the mutants are displayed in Figures 14-15
and the results are summarized in Table 8. The only interface mutants that appeared blue in the
screen were W277C and F273C/N278C (very faint blue appeared much later). All of the
interface mutants were explored in shake flasks to observe if any activity could be detected in
culture. The only active site mutants that retained activity were E203C, Y207W, and
E203C/Y207W. Y207W appeared clearly blue in several hours, but E203C and E203C/Y207W
turned blue given more time incubating (Figure 15). The active site mutations (E203C,
Y207W, and E203C/Y207W) giving a blue result, were analyzed further in shake flasks. The
only glycosylation mutants to lose activity were Trp209X/Asn215Gln (W209X/N215Q) and
Phe211His/Asn215Gln (F211H/N215Q); Met208X/Asn215Gln (M208X/N215Q) retained very
slight activity that was only observed after overnight incubation so none of these mutants were
evaluated further. All of the other third glycosylation site mutants were evaluated in shake
flasks.
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A) Interface Mutants

F273C

Chosen for
purification
yes

W277C

yes

F273C/W277C

no

F273G/W277G

yes

F273C/N278C

yes

Mutation

B)

Blue/White screen activity

Active Site Mutants
Mutation

Chosen for
purification

Y207W

yes

E203C

yes

E203C/Y207W

yes

D170C

no

E203N

no

E203C/ W204C/P205X/
L206X/Y207W

no

E203C/ W204N/P205X/
L206X/Y207W

no

Blue/White screen activity

Figure 14. Blue/White X-gal screen of interface and active site mutants. A) First row of the image contains
controls of wild type α-Gal and X-33. Second row contains all of the interface mutants. B) The first image
contains the active site mutants E203C/W204N/X/X/Y207W, and E203C/W204C/X/X/Y207W from one
plate. The second contains E203N from another, and the last contains the remaining active site mutants.
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A) 3rd Glycosylation Site Mutants

Mutation

Chosen for
purification

M208E/N215Q

yes

M208E/F211H/
N215Q

yes

F211H/N215Q

no

M208X/N215Q

no

W209X/N215Q

no

F211X/N215Q

yes

N215Q

yes

M208E

yes

Blue/White screen activity

B) ) humanized P. pastoris strain (SuperMan 5)

A) Mutation

Chosen for
purification

Wild type

future studies

F273C

no

Blue/White screen activity

Figure 15. Blue/White X-Gal screen of A) glycosylation mutants. B) humanized P. pastoris strain
(SuperMan 5) containing the wild type α-Gal and the F273C mutation.
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Table 8. All constructed mutants and results of blue/white screen.
Blue/White screen activity
Mutation
Location
Y207W

blue

E203C

light blue

E203C/Y207W

light blue

D170C

Active site

white

E203N

white

E203C/W204C/P205X/L206X/Y207W

white

E203C/W204N/P205X/L206X/Y207W

white

F273C

white

F273G

N/A

W277C

blue

W277G

Interface

N/A

F273C/W277C

white

F273G/W277G

white

F273C/N278C

very faint blue

M208E/N215Q
M208E/F211H/N215Q

blue

F211H/N215Q

white

M208X/N215Q

blue
Third Glycosylation Site

very faint blue

W209X/N215Q

white

F211X/N215Q

blue

N215Q

blue

M208E

Loop between the active
site and the third
glycosylation Site

blue
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Secondary screening of mutant enzyme produced in shake flasks
Culturing and purification in shake flasks
Four shake flasks were cultured for seven to nine days and growth and α-Gal production
were monitored daily via optical density absorbance at 600 nm and enzyme assay respectively.
The growth and production curves for the wild type are displayed in Figure 16. The time of
culture was determined based off enzyme production, longer durations were used for less active
strains. The four flasks were harvested together and pooled for purification. The SDS-PAGE
results using both column purification techniques are represented in Figure 17, and the
purification tables are shown in Tables 9 and 10.
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Table 9. Wild type Purification Table
Protein
Concentration
Step
(mg/mL)
Supernatant 0.714
0.15
DEAE
0.03
Thio-gal

Enzyme
Activity
(units/mL)
9,315
8,040
15,225

Specific
Activity
(units/mg)
13,046
53,600
507,500

Fold
Purification
1.00
4.11
38.9

%Yield
100%
80%
20%

Table 10. E203C/Y207W Purification Table
Protein
Concentration
Step
(mg/mL)
Supernatant 1.450
0.361
DEAE
0.023
SP

Enzyme
Activity
(units/mL)
4,545
6,450
2,276

Specific
Activity
(units/mg)
3,134
17,867
98,935

Fold
Purification
1.00
5.70
31.6

%Yield
100%
85%
10%
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A)OD600

B) Units/ml

Growth of PC626 (wildtype a-gal)

a-Gal Expression
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6000
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A
B

1
0

2

4

6

8

C
D
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Units/mL

5000
4000

A

3000

B
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C
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D

0
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0

2

4
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8

Figure 16. A) Growth of P. pastoris in shake flasks monitored by optical density. B) Production of
wild type α-Gal in shake flasks. The four curves represent individual cultures in parallel.

Figure 17. SDS-PAGE of wild type α-Gal purification with DEAE and Thio-gal (left). SDS-PAGE of
E203C/Y207W α-Gal purification with DEAE and SP (right). 71.1 is the harvest, 71.2 is diafiltrated
sample, 71.4 is the DEAE pool, and 71.7 is the concentrated SP pool.
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Comparison of the kinetics of α-Gal mutants
The kinetic results for the purification from shake flasks of all mutants are summarized in
the appendix (Tables 26 and 27). Tables 11 and 12 highlight the kinetics of the mutants that
were stable enough to undergo purification. There were two different continuous assays used to
generate this data one with an excitation at 360 nm and emission at 465 nm and the other at 315
nm and emission at 450 nm. See Chapter 4 on the details of these assays. Due to the fact that
the two assays do not provide comparable data to each other and kinetics are most accurate
before freezing, Tables 11 and 12 represent the most accurate data for each mutant. Most of the
mutants’ relative efficiency (kcat/Km) was less than the wild type irrespective of the assay used.
However, three mutants showed an increase in efficiency: Y207W; M208E/N215Q; and
F211X/N215Q. Y207W is the single active site mutation that was observed in C. josuil, S.
cerevisiae, and P. chrysosporium. This residue does not bind to the substrate according to the
catalytic mechanism(1), but it is involved in the stabilization by hydrogen bonding of the
hydroxyl of the Tyr to the carbonyl of D170, which is the residue that initiates catalysis by its
nucleophilic attack on the anomeric carbon of the galactose. We hypothesize that the mutation
of this residue to a Trp prevents this hydrogen binding stabilization, increasing the reactivity of
D170, which is observed in the greater than 2-fold increase in Vmax. The Km is slightly decreased
(less than 2-fold) as well, which could be explained as a byproduct of the change in equilibrium
of the reaction with the increase in catalysis.
Mutants M208E/N215Q and F211X/N215Q are both third site glycosylation knockouts
with the additional modification to the hydrophobic loop. The M208E allele is the residue next
to the active site in the primary sequence but in three-dimensional space, the R group faces away
from the active site residue Y207, due to the trans nature of peptide bonds. The stability of this
49

sample was impaired, making it unable to be tested using the new continuous assay, so it seems
that the increase in kinetic efficiency is more of an unexpected effect of catalysis than stability.
One possible explanation is the mutation to a hydrophilic residue allows for more water
molecules to be available for the second substrate in the catalytic mechanism. Further study was
done for the M208E mutation with the glycosylation intact, and that mutant was cultured in the
bioreactor directly. F211X is possibly increasing activity with a similar mechanism as the
M208E mutation, but since the residue is further from the active site, the change is less drastic,
which might explain the increase in Vmax observed with no change to the Km. The Y207W,
M208E, E203C/Y207W, and W277C mutants were scaled up to the bioreactor for further
analysis. M208E/N215Q and F211X/N215Q were not scaled up due to the observed decrease in
stability.
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Table 11. Non-linear regression of mutants assayed at an excitation of 315 nm
Location of
Mutation
N/A

Active Site

Glycosylation

Mutation

Km
(mM)

Vmax
(mmol/hr/mg)

kcat
(s-1)

kcat/Km
(M-1s-1) * 103

Relative
kcat/Km
to WT

Wild
type

1.10 ±0.06

0.067 ± 0.0029

1.68 ± 0.07

1.52 ± 0.03

1.00

E203C

1.68 ± 0.25

0.041 ± 0.0048

1.01 ± 0.12

6.04 ± 17

0.399

Y207W

0.62 ± .08

0.177 ± 0.0077

2.93 ± 0.19

4.75 ± 0.28

3.11

E203C/
Y207W

1.02 ± 0.11

0.045 ± 0.0017

1.12 ± 0.04

1.10 ± 0.07

0.84

F211X/
N215Q

0.98 ± 0.12

0.207 ± 0.0123

5.18 ± 0.31

5.33 ± 0.36

3.50

M208E/
F211H/
N215Q

1.51 ± 0.62

0.045 ± 0.0147

1.12 ± 0.32

0.756 ± 0.06

0.50

N215Q

1.28 ± 0.15

0.019 ± 0.0011

0.48 ± 0.03

0.380 ± 0.22

0.25
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Table 12. Non-linear regression of mutants assayed at an excitation of 360 nm
Mutation

Km
(mM)

Vmax
(mmol/hr/mg)

kcat
(s-1)

kcat/Km
(M-1s-1) *
103

Relative
kcat/Km
to WT

N/A

Wild
type

0.668
±0.026

0.028 ± 0.0004

0.71 ±
0.01

1.06 ± 0.03

1.00

Interface

W277C

0.56 ± 0.04

0.018 ± 0.0008

0.45 ±
0.02

0.80 ± 0.02

0.746

Glycosylation

M208E/
N215Q

0.46 ± 0.05

0.11 ± 0.0015

2.75 ±
0.04

5.98 ± 0.58

5.62

Location of
Mutation

52

Quaternary structure of α-Gal
There was no change in molecular weight of the wild type enzyme observed under any of
buffer conditions investigated; only the two overlapping peaks of dimer were observed. The
peaks are consistent with the multiple molecular weights observed on the SDS-PAGE resulting
from multiple glycoforms of the wild type enzyme produced in P. pastoris. Only one of the
interface mutants was successfully purified from the shake flasks (W277C), and this mutant was
analyzed under the same condition as the wild type. The majority of protein in the W277C
sample was an aggregated high molecular weight species, consistent with an octamer, with a
minor peak being the dimer as observed in Table 13.
Table 13. Molecular weights of purified enzymes.
Molecular Weight (kDa)
Major peak Minor peak
Wildtype
126-106
W277C
511-364
85
Sample

Thermostability analysis
Initially all successfully purified mutants from shake flasks with the exception of
M208E/N215Q were analyzed for their relative thermostabilities in comparison to the wild type
using the continuous assay at 42oC. M208E/N215Q was excluded because it was so unstable it
did not survive freeze thaw. The goal was to observe, in real time, the denaturation of each
mutant by observing a plateau or a decline in the fluorescence of MU the product over time
(Figure 18). Unfortunately, this inflection or plateau was difficult to determine experimentally,
and an alternative assay was developed that is described in the methods section.
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The data obtained for the water bath stability analysis of the purified mutants from shake
flasks is presented in Figure 19. With the exception of N215Q all glycosylation mutants were
not evaluated for thermostability because they lost activity prior to the second stability analysis.
This experiment however, is not a completely valid comparison of each mutants’ stability
because there are other variables that may confound the results. The mutants were not all in the
same buffer, so there is a variation in pH as well as conductivity, and the concentrations of the
enzymes were not standardized. It has been observed in this lab that wild type α-Gal increases in
stability with greater concentration. The summary of these differences is displayed in Table 14.
Despite these confounding variables, there is one significant observation to emphasize, W277C
(interface mutant) is remarkably stable. The concentration of W277C is comparable to E203C
(active site mutant), and the buffers are the same, yet after two hours at 50oC E203C had lost all
of its activity whereas W277C retained 50% activity. There is little reason to suspect that the
difference in stability observed between E203C and the wild type is more than just the 10 fold
difference in the concentration of enzyme, because a mutation within the active site pocket is not
likely to affect stability. Due to this observed increase in stability W277C was cultured in the
bioreactor for further study.
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Stability of mutant α-Gal from shake flasks
3950000
3450000
WT

2950000

F211X/N215Q

FU/mg

2450000

M208E/F211H/N215Q
1950000
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W277C

950000

E203C
Y207W

450000

E203C/Y207W

-50000
0
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60
Time (min)
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Figure 18. Comparison of the thermostablity of the mutants to the wild type prepared form
shake flasks as observed as fluorescence over time.

Stability of Mutants from shake flasks at 50
degrees Celcius
120%

% Original Activity

100%
WT

80%

W277C
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Figure 19. Comparison of the thermostability of the mutants to the wild type prepared from
shake flasks observed as percent initial activity over time. The wild type and E203C/Y207W
overlap with N215Q.
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Table 14. Variables in shake flasks thermostability analysis.
Concentration of
Mutant
Buffer
Enzyme (mg/mL)
WT
0.006
10 mM Sodium Phosphate pH 6.5
W277C
0.063
10 mM Sodium Phosphate pH 6.5
E203C
0.077
10 mM Sodium Phosphate pH 6.5
Y207W
0.014
10 mM Sodium Phosphate pH 6.5
25 mM Citrate- Phosphate pH 4
E203C/Y207W
0.023
250 mM Sodium Chloride
25 mM Citrate- Phosphate pH 4
N215Q
0.035
250 mM Sodium Chloride
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In depth analysis of mutants expressed in a bioreactor
Production and purification of enzymes in a bioreactor
The process of producing α-Gal in a bioreactor has been developed in this lab (30).
Culturing in the bioreactor allows for greater control over variables such as pH, dissolved
oxygen, and temperature, which elevates the production of enzyme as well as increases the
volume of culture. The growth, measured by wet weight, and the production of α-Gal, measured
by enzyme assay, for the wild type is shown in Figure 20. Wild type enzyme was produced and
purified using DEAE and Thio-gal in order to compare the kinetics using the new continuous
assay to the most efficient mutants identified (Y207W, M208E, E203C/Y207W, W277C) and to
the published values. The active site mutants were purified with an SP column as a second
column, and Y207W required an additional step of using a Superdex G200 (GE healthcare). The
W277C and M208E mutants were purified with the Thio-gal column as the second column. The
SDS-PAGE analyses for each purification are located in Figures 21-23, and the purification
tables are summarized in Tables 15-18.

Wet Weight
Activity

Figure 20. Wild type α-Gal production in a bioreactor. The black line is the wet weight readings and
the brown line is the activity of α-Gal.
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A) SDS-PAGE of WT α-Gal

B) Purification table for WT α-Gal

Aliquot

Step

Protein
Concentration
(mg/mL)

Enzyme
Activity
(units/mL)

Specific
Activity
(units/mg)

Fold
Purification

%Yield

77.1

Supernatant

6.046

19,388

3,207

1.00

100%

77.2

Diafiltration

3.404

104,175

30,604

9.54

67%

77.5

DEAE

0.634

125,850

198,502

61.90

41%

77.10

Thio-gal

0.001

4,598

4,597,500

1,434

1%

Figure 21. A) SDS-PAGE of purification 77 is the wild type. B) The purification table identifies
the sample in each lane.
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Figure 22. SDS-PAGE of purification 79 is the E203C/Y207W mutant
(Table 14) and 80 is the W277C mutant (Table 15). The purification
table identifies the sample in each lane.

Table 15. E203C/Y207W Purification Table

Protein
Concentration
Aliquot Step
(mg/mL)
79.1
Supernatant 4.04
79.2
Diafiltration 4.06
79.23
DEAE
0.353
79.24
SP
0.005

Enzyme
Activity
(units/mL)
1,715
9,188
5,123
2,418

Specific
Activity
(units/mg)
425
2,263
14,511
483,600

Fold
Purification
1.00
5.33
34.18
1,139

%Yield
100%
67%
1.9%
0.4%

Table 16. W277C Purification Table

Protein
Concentration
Aliquot Step
(mg/mL)
80.1
Supernatant 3.023
80.2
Diafiltration 0.9

Enzyme
Activity
(units/mL)
2,880
9,263

Specific
Activity
(units/mg)
953
10,212

Fold
Purification %Yield
1.00
100%
10.7
75%
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80.6
80.11

DEAE
Thio-gal

0.396
0.004

5,655
29,363

14,280
7,340,625

15.0
7,705

20%
5%

Figure 23. SDS-PAGE of purification 81 is the Y207W mutant (Table
16) and 82 is the M208E mutant (Table 17). The purification table
identifies the sample in each lane.

Table 17. Y207W Purification Table

Protein
Concentration
Aliquot Step
(mg/mL)
81.1
Supernatant 4.159
81.2
Diafiltration 1.0
81.6
DEAE
0.195
81.7
SP
0.016
81.15
SEC
0.0004

Enzyme
Activity
(units/mL)
2,925
3,664
10,035
923
360

Specific
Activity
(units/mg)
703
3,735
51,462
57,656
898,750

Fold
Purification
1.00
5.31
73.2
82
1,278

%Yield
100%
50%
69%
0.09%
0.02%
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Table 18. M208E Purification Table

Aliquot
82.1
82.2
82.6
82.8

Step
Supernatant
Diafiltration
DEAE
Thio-gal

Protein
Concentration
(mg/mL)
4.043
0.9
0.632
0.012

Enzyme
Activity
(units/mL)
46,650
304,500
171,300
101,250

Specific
Activity
(units/mg)
11,538
344,847
271,044
8,437,500

Fold
Purification
1.00
29.9
23.5
731.3

%Yield
100%
135%
46%
1%

Purified α-Gal from P. pastoris often exists in multiple glycoforms and can appear as
multiple bands on an SDS-PAGE. These bands have been previously identified as α-Gal by
western blot(30) and by digestion with Peptide-N-Glycosidase F (9). In the case of the Y207W
mutant (81.15), there were some difficulties during the purification. Although a band is not
visible in this image, it was visible with the eye and slightly more apparent on a native gel in
Figure 28 (Quaternary structure section). Due to the issues in purification and the extremely low
concentration the Y207W mutant likely lost a large amount of activity, and therefore the
subsequent characterization experiments may be a bit misleading. The low yields in many of the
cases are the result of a separation of the pool at key steps to serve as a back-up. This result was
especially necessary for the SP purified mutants because of the need to trouble shoot the scale up
to the bioreactor. In the case of the mutants purified using Thio-gal chromatography, the
majority of the enzyme consistently fails to bind the resin, independent of the amount loaded.
We hypothesize that the different glycoforms bind with varying affinities, which was observed
with the purification of the third glycosylation site knockouts from the shake flasks having a
much better binding capacity.
Kinetic analysis of mutants purified from the bioreactor
The kinetic analysis of the mutants purified from bioreactors rendered different results
than was observed in the shake flasks, not only in the quantitation of the Vmax or Kcat but the
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relative efficiency was not always consistent with the shake flask data. The kinetic results of the
wild type to validate the change in assay from the time point assay to the continuous assay for
detection are summarized in Table 19. Details on the assay are described in the next chapter.
The summarized results of the non-linear regression analysis for all mutants are located in Table
20. Two of the mutants explored, W277C and M208E appeared to deviate from the expected
Michaelis-Menten rectangular hyperbola and were sigmoidal consistent with positive
cooperativity. The substrate saturation curves and Eadie plots are displayed in Figure 24 for the
wild type, W277C, and M208E. W277C displayed a Hill coefficient (coefficient to determine
degree of cooperativity) of 4.6 ± 0.99, which is inconsistent with a dimeric species, so further
experiments were used to characterize this mutant in particular. M208E is less sigmoidal with a
Hill coefficient of 3.47 ± 1.36, but is not consistent with only two binding active sites. It was
previously observed in the crystal structure of α-Gal that there is a secondary binding site per
monomer that binds β-D-galactose as opposed to α-D-galactose, which is bound by the active
site and is a known competitive inhibitor. The authors of the paper other than identifying the site
have not determined the site’s function in the wild type (55). It was hypothesized that this
secondary site might be involved in some allosteric effect that is more pronounced in the
mutants, and this hypothesis was explored further. There is no evidence for any cooperative
binding of MUG to wild type α-Gal in the literature or observed in this lab, however there is
report of a Hill coefficient of 1.9 of the natural substrate, Gb3, to the wild type enzyme,
identifying a precedent of positive cooperativity(56).
These two mutants were the only observed to increase the relative efficiency of catalysis
2 to 3-fold. M208E increased the Vmax of the enzyme with little observed change to the Km or
K0.5, since the curve does not fit a Michaelis-Menten prediction. This result is consistent with
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the initial hypothesis that mutation to a hydrophilic residue increases the availability of water for
catalysis. W277C decreased the Km or K0.5 with little observed improvement to the Vmax. Since
this mutation is located in the interface with an extremely high Hill coefficient, the cooperativity
between the subunits is likely affecting the binding of the substrate.
Both active site mutants (Y207W and E203C/Y207W) appear to decrease the efficiency
of the enzyme, and in the case of Y207W, that is inconsistent with the shake flask result. Since
this mutant was unable to be purified the same way from shake flask to bioreactor the issue
might be a result of the third column drastically diluting the enzyme and compromising the
stability. This stability issue would explain the decrease in the Vmax observed, but it is possible
that the bioreactor is the true result. There is enough ambiguity to this mutant’s result to warrant
further investigation as well as the development of an optimized purification procedure. The Km
observed is consistent in being lower than the wild type to the shake flask result. However, if
this result is confirmed through further testing, the initial hypothesis does not hold up because
the Vmax is less than the wild type. In the event that the purification is optimized and the stability
is maintained there is reason to believe that the shake flask trend may be confirmed. The trend
for E203C/Y207W is fairly consistent between the shake flasks and the bioreactor. Both result
in a decrease in relative efficiency, with no significant change to the Km, but a decrease in the
Vmax. The only difference of note is the degree of the decrease observed between the bioreactor
and the shake flasks. The shake flasks observe a twofold decrease, whereas the bioreactor
demonstrates a fourfold decrease. It is important to clarify that the quantification of the Vmax is
always significantly lower in the shake flasks than in the bioreactor, so that very well could
explain the discrepancy. The difference between 0.045 and 0.067, observed in the shake flasks
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of E203C/Y207W and the wild type respectively, and 0.43 and 2.25, detected in the bioreactor
could just be a side effect of the increase in magnitude.
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Table 19. Comparison of kinetic parameters of wild type enzyme purified from a
bioreactor using the time point and the new continuous assay
Assay
Time
point(30)
Continuous
LineweaverBurke
Continuous
Non-Linear
Regression

Excitation
Emission
360nm
465nm

Km
(mM)
2.44 ±
0.44

Vmax
(mmol/hr/mg)

Kcat (s-1)

Km/Kcat (M-1 s-1)

3.36 ± 0.25

84

34,400

315 nm
450nm

2.14 ±
0.07

2.96 ± 0.183

74.1 ± 4.58

34,026 ± 982

315 nm
450nm

1.48 ±
0.09

2.25 ± 0.141

56.2 ± 3.53

38,026 ± 447
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Table 20. Comparison of kinetic parameters of wild type enzyme to all mutants purified from a
bioreactor using the new continuous assay and non-linear regression with Prism
Mutant
Wild type
E203C/Y207W
Active Site
Y207W
Active Site
W277C
Interface
M208E
Loop

Km or K0.5
(mM)

Vmax
Kcat (s-1)
(mmol/hr/mg)

kcat/Km
(s-1 M-1)

Hill
coefficient

Relative
Kcat/Km

1.48 ± 0.09

2.25 ± 0.14

56.2 ± 3.53

38,026 ± 447

1.00

1.00

2.09 ± 0.72

0.43 ± 0.12

10.7 ± 3.09

5,203 ± 281

1.00

0.14

1.10 ± 0.02

0.76 ± 0.03

19.1 ± 0.72

17,309 ± 408

1.00

0.46

0.70 ± 0.05

2.46 ± 0.19

61.4 ± 4.85

87,809 ± 8,169

4.60 ± 0.99

2.31

1.12 ± 0.33

5.08 ± 1.44

127 ± 35.9

114,431 ± 3,439 3.47 ± 1.36

3.01
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Figure 24. Subrate saturation data (a) and an Eadie plot (b) for the wild type in comparison to the
mutants M208E (c and d) and W277C (e and f).
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Quaternary structure of α-Gal and effect of galactose
The initial shake flask high molecular weight and the high Hill coefficient observed for
W277C indicated that the quaternary structure of the bioreactor sample should be investigated
further. When the same size exclusion chromatography experiment was repeated with the
W277C mutant purified from the bioreactor the shake flask potential octameric result was not
reproduced. In that experiment, the molecular weight of W277C was calculated to be 108.3 kDa,
consistent with a dimeric species, in a sharp single peak of only one observed glycoform (Figure
25). The observed dimer was unexpected for W277C, given the high Hill coefficient observed.
Upon further analysis of the predicted structure of the monomer of W277C, generated by
PHYRE, in comparison to the crystal structure of the wild type(4) (PDB code 3HG2) containing
the secondary binding site in PyMOL, there was a perceived structural change to the secondary
binding site. This site has been reported to selectively bind β-D-galactose; however the
predicted structure of W277C resulted in a change in positioning of the side chain of the
glutamine (Gln250) in that secondary site. The amide of this glutamine is in the location of the
anomeric carbon of the galactose giving more room for an axial hydroxyl, α-D-galactose, as
opposed to selecting exclusively for a β-D-galactose. Figure 26 depicts the binding of the
galactose in the wild type, illustrating the location of the glutamine.
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This observation, lead to the hypothesis that this secondary site was causing galactose to
act as an allosteric activator in the mutant. To test this hypothesis, the wild type and the mutant
were analyzed side by side in the presence of varying concentrations of galactose. There
appeared to be no difference between the two in terms of activity. Galactose appears to be solely
an inhibitor for both (Figure 27) with an inhibitor concentration of 50% (IC50) of approximately
10 mM for both.

Figure 25. Size exclusion chromatography A280 profile of the purified wild type enzyme (left) and the
purified W277C mutant (right) produced in bioreactors and analysis carried out in 10 mM sodium
phosphate buffer pH 6.5 and 100 mM sodium chloride.
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Figure 27. β-D-galactose bound to secondary site in the wild
type (PDB 3HG2(4)). Image generated in PyMOL. The amide
of Gln250 is depicted in blue.

Effect of Galactose on % Activity
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Figure 26. Effect of galactose on activity A) %Activity versus concentration
of galactose. B) Inhibitor Concentration 50% graph, %Activity versus log10
galactose
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Although the structure appeared to be a dimer in on the size exclusion chromatography,
this was determined in the absence of galactose. Despite the fact that galactose was shown to not
be an activator of W277C, this does not preclude a difference in the structure of the mutant to the
binding of galactose, which could explain the sigmoidal curve observed. It has been previously
observed in the literature that galactose can act as a molecular chaperone and affect the folding
mutant enzymes associated with disease as well increase the thermostability of the wild type
enzyme (57). We hypothesized that the mutant would undergo a structural change in the
presence of galactose, which we evaluated by native gel in the presence and absence of galactose
compared to the wild type as well as the M208E mutant. The native PAGE with galactose and
without galactose showed a retarded migration of W277C compared to the wild type, Y207W,
and M208E (Figure 28). This indicates that the change in structure is independent of galactose
presence.

Figure 28. Native gel of mutants in the presence of 50 mM galactose (left) and in the
absence of galactose (right).
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Thermostability
The stability analysis of the purified bioreactor samples was tested using the same
method as the shake flasks; to mitigate the differences in concentration and buffer, all the
samples were concentrated using an Amicon centrifuge filter (Millipore) and buffer exchanged
into 25 mM citrate-phosphate buffer pH 4. Figure 29 depicts the relative thermostabilities of all
of the purified mutants from bioreactors with the exception of Y207W. The concentration of the
Y207W mutant was too low in comparison to the other samples for a fair comparison. The final
concentrations for all of the stability samples were diluted down to 0.006 mg/mL, which was the
concentration for the wild type in the shake flask stability experiment. The stabilities are more
or less the same for all of the mutants and the wild type in a standardized buffer and
concentration. The W277C enzyme appears slightly more stable than the rest at 20% activity at
15 min as opposed to approximately 10% for the other samples, but in the absence of replicates
there is no assurance in the significance of that observation. The difference between the stability
observed for W277C in the shake flasks and the bioreactor is likely a factor of the tenfold
difference in concentration.
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Stability of Mutants from bioreactor at 50
degrees Celcius
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Figure 29. Comparison of the thermostability of the mutants to the wild type
prepared from bioreactors observed as percent initial activity over time.
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Discussion
Mutations were constructed in an attempt to increase catalysis, increase stability, and to
test the theory that the enzyme might become glycosylation independent. The active site was
targeted to increase the activity of the enzyme using homology modeling as well as organic
chemistry principle design. Seven active site mutants were constructed of which three retained
activity and four did not. Of the four that lost activity, Glu203Asn (E203N),
E203C/W204C/P205X/L206X/Y207W, and E203C/W204N/P205X/L206X/Y207W were
constructed based on homology modeling. We hypothesize that E203N lost activity because the
amide group was unable to hydrogen bind to the galactose, which rendered the enzyme unable to
bind the substrate. In the E203C/W204C/P205X/L206X/Y207W and
E203C/W204N/P205X/L206X/Y207W mutants it is possible that in the human enzyme the
residues were too close to each other to correctly promote catalysis. Since the E203C/Y207W
enzyme retained activity at a distance of three residues in an α-helix as opposed to one residue in
a predicted loop, it was not the cause for the loss of catalysis observed. In the case of D170C it
is possible that either the thiol did not act as a nucleophile because it was perhaps too far away
from the anomeric carbon or it reacted but failed to release the galactose product resulting in
irreversible inhibition.
The interface was targeted for mutation in the intention of increasing the stability of the
enzyme while not decreasing the catalysis. Mutants F273C/W277C and F273C/N278C were
constructed in an attempt to stabilize the dimer using two disulfide bonds across the interface
rather than aromatic stacking. The blue/white screen indicted that even if the disulfide bond was
formed the activity was severely compromised. The F273G/W277G mutant was constructed
because it was previously reported to be an active monomer (48). A monomeric form of α-Gal
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would be therapeutically useful because smaller molecules are able to be taken up into podocytes
better, which is a primary accumulation site of substrate in Fabry disease. The blue/white screen
indicted that if the mutant formed a monomer the activity was severely compromised to the point
it was undetectable. F273C and W277C were constructed to stabilize the dimer using
thiol/aromatic interactions. F273C was completely inactive whereas W277C retained decent
activity. We hypothesize that F273’s location on a loop as opposed to W277’s location on an αhelix allowed for greater flexibility for the thiol/aromatic interaction between the π electrons of
the phenyl ring of F273 and the thiol of W277C, than an interaction between the π electrons of
the indole ring of W277 and the thiol of F273C.
The last target for mutation was the hydrophobic loop between the active site and the
third glycosylation site N215 in an attempt to construct a glycosylation independent enzyme.
The glycosylation was removed by a mutation of N215Q, so all subsequent mutants were at least
double mutations containing this mutation. Two approaches were utilized to mitigate this
hydrophobic patch: one was introducing substitutions based on the primary sequence of the
Zebrafish which does not have a glycosylation site at that region; the second was deletion of the
hydrophobic residues shortening the loop. Most of these mutants retained activity; the only two
that completely eliminated activity were F211H/N215Q, from the Zebrafish, and the deletion
W209X/N215Q. Interestingly the triple mutant M208E/F211H/N215Q retained activity, but the
activity was lower than the M208E/N215Q indicating that the F211H mutation decreases activity
but that an additional hydrophilic residue can overcome it. The predicted structure of the F211H
mutation depicts the His side chain in close proximity to the Met side chain, which could explain
this observation. The predicted structure of the W209X/N215Q mutant projects that the deletion
of the Trp results in a complete disruption of the α-helix in the active site, which would explain
75

the loss of activity. The M208X/N215Q allele severely decreased the activity observed but some
was retained. The large increase in activity observed in the M208E/N215Q, lead us to
hypothesize that this was a result of an increase in catalysis not stability. The M208E allele was
constructed containing the glycosylation site to further investigate this, and high activity was
observed.
The use of a screening procedure involving an initial production and screening in shake
flasks is an effective tool for determining which mutants are appropriate for further study.
However, the results gathered should not be considered definitive, as these results have shown.
There are significant discrepancies observed between the shake flasks results and the bioreactor
results as to quantification, yet there appeared to be a trend. The interface mutant, W277C, was
determined to be positively cooperative and more active in the bioreactor. In the shake flasks the
sigmoidal curve was extremely slight and was only noticed after the results for bioreactor were
obtained, however on re-examination and curve fitting with a sigmoidal function the Km/K0.5 was
determined to consistent with the bioreactor results. The Hill coefficient from the shake flask
data was significantly less, 1.32±0.24, than the bioreactor result of 4.60±0.99, but the shake flask
result is more consistent with a dimeric species.
Further analysis needs to be done to explain the extreme positive cooperativity observed
in this mutant that deviates from the literature which states that the Hill coefficient should not
exceed the number of binding sites (58). The size exclusion chromatography has determined the
structure to be dimeric; the native PAGE identifies a slightly retarded migration however, that is
observed with or without galactose, which does not contradict the size exclusion result. Since
the migration on the SDS-PAGE is the same as the wild type the best interpretation of all of
these results that W277C causes a significant conformation change (native PAGE) but is still a
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dimeric species. The significant change in conformation is most plausible since the mutation
occurs at the dimer interface. The substitution of a tryptophan to a cysteine can very well cause
shifting of the axis of the association of the two monomers, which can be causing the
cooperativity observed. This explanation is entirely theoretical in the absence of a crystal
structure or a model to predict quaternary structure with any accuracy.
The inhibition observed with galactose was indistinguishable from the wild type
indicating that galactose is not binding and activating the mutant at the secondary site. There
have been reports that the E. coli enzyme threonine deaminase varies in Hill coefficient
depending on the binding of different compounds to the enzyme such as valine (1.0), isoleucine
(3.9), or the absence of effectors (2.3) (59). One possible explanation in regards to this
phenomenon is that the substrate, itself is binding to the secondary site and activating the
catalysis, however many more studies would be needed to determine that. The possible increase
in stability observed in this mutant should be further investigated as well.
The results for the M208E mutant cannot be directly compared to the shake flask results
of M208E/N215Q, but the stability being comparable to the wild type can be explained by the
retention of the glycosylation. The relative increase in catalysis observed being consistent with
both mutants gives more support to the initial hypothesis that the increase in activity observed
was independent of the glycosylation and an unexpected effect on the active site. The presence
of a hydrophilic residue, glutamate, adjacent to the active site as opposed to a highly
hydrophobic residue, methionine, may increase the water molecules available to bind as the
second substrate in the ping-pong bi-bi reaction (1) which in turn increases the rate of catalysis
(Vmax). There is a slight improvement in the Km or K0.5, but the more interesting phenomenon is
the appearance of positive cooperativity in this mutant as well. The Hill coefficient for this
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mutant is 3.47±1.36, which is higher than would be expected for a dimer; however in light of the
large standard deviation it is not necessarily so large that it is unbelievable. The Native PAGE
indicates that the quaternary structure of M208E is similar to the wild type, and unlike W277C;
there is no reason to believe that there is a large confirmation change. In light of the previous
observation of the wild type enzyme undergoes positive cooperativity with Gb3 but doesn’t with
MUG (7). It is possible that this mutation exacerbates the unknown mechanism that result in the
substrate distinction.
The most obvious inconsistency between the bioreactor results and the shake flask results
is shown in Y207W. The shake flasks identified a 3-fold increase in efficiency as compared to
the wild type, with improvement in both Vmax and Km, yet the bioreactor showed a 2-fold
decrease in efficiency retaining the improvement to Km but resulting in a 3-fold decrease in Vmax.
Although this is a concerning discrepancy, it is at the same time misleading. Although the
Y207W mutant was successfully purified with DEAE and SP in shake flasks it was unable to be
purified utilizing the same method from the bioreactor. Additionally confounding is the
observation that E203C/Y207W was successfully purified using that method in both. Y207W
could not be purified on Thio-gal because loading the enzyme on the column on multiple
occasions resulted in complete inactivation of the enzyme. We hypothesized that this was
because α-Gal binds Thio-gal at the active site, which is the location of the Y207W mutation.
Due to the substantial difficulties purifying this particular mutant, it is reasonable to be skeptical
of the decrease in Vmax observed. Had the enzyme only gone through a two-column purification
like the others and resulted in more concentrated enzyme; it would be a more valid comparison.
For this reason it may be worth developing a more optimal purification procedure for this mutant
in the future.
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The results from the shake flasks and the bioreactor are consistent for the E203C/Y207W
mutant. Both methods determined that this mutation resulted in a decrease in efficiency in
comparison to the wild type particularly in regards to catalysis (Vmax). The reason this mutant
was selected for study in the bioreactor was to better characterize the difference between the
double mutant and the single mutant Y207W. Due to the issues previously mentioned with
Y207W this analysis has not been fully carried out and should be looked into in the future.
From a therapeutic perspective, the best candidates put forward from this research are
W277C and M208E. Y207W upon optimization may also prove to be a likely option as well.
The threefold increase in catalysis observed with M208E may result in a lower dose necessary
for patients. The twofold increase in catalysis observed with W277C as well as the potential
increase in stability may result in a lower dose or a longer time between infusions for patients.
Lower dosage would in turn decrease the immune response experienced by patients (21).
Another mutation that may be worth looking into would be a glycosylation intact F211X. It
would be interesting to investigate if the increase in catalysis observed in the shake flasks was
due to that mutation or the elimination of a potentially hindering carbohydrate chain.
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Chapter 4 : Development of a Continuous Kinetic Assay
Overview
Most kinetic data for α-Gal is determined using either a fluorescent assay with a synthetic
substrate MUG (32) or a colorimetric assay with a synthetic substrate para-nitrophenyl-α-Dgalactopyranoside (PNPG) (3). These assays utilize a method of termination of the reaction with
the presence of a base and varying time points to determine the rate of the reaction. Although
effective, this method has many limitations such as a low limit to the amount of substrate
concentrations used in a saturation curve and many opportunities for human error. Previous
work has developed a continuous assay using MUG that allows for rate of reaction to be
determined in real time by a plate reader decreasing the human error element (60). The issue
with this method was the intensity of the fluorescent product, MU, in acidic pH which is
necessary for the reaction to occur, is ten-fold lower than in basic pH. This difference in
intensity often makes the determination of kinetic parameters difficult to compare to the time
point method in basic pH. This research presents optimization of a continuous assay with MUG
for more rapid and accurate measurements of kinetic parameters of human α-Gal.
Methods and Materials
Identification of Optimal Wavelengths for Excitation and Emission
The substrate (MUG) and the product (MU) of the assay were scanned in both 0.1 M
sodium acetate pH 4.6 and 0.1 M diethylamine pH 11 using a Hitachi U2910 UVVIS spectrophotometer from 200-600 nm to determine the wavelength of maximum absorbance
and to identify the optimum excitation wavelength. These results were then confirmed with a
PerkinElmer LS 55 Fluorimeter excitation wavelength scan at an emission of both 380 nm and
445 nm, the maximum emission peaks for MUG and MU respectively. The samples were then
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subjected to an emission wavelength scan in the same solutions using a PerkinElmer LS 55
fluorimeter from 300-700 nm at the excitation wavelengths determined from the
spectrophotometer.
Development of a Continuous Enzyme Assay
Once the excitation wavelength was determined, the continuous assay was performed
using the excitation at 360 nm and 315 nm and compared to the time point assay at high pH. The
assays were performed in a Tecan Infinite F200 series, and units were determined in comparison
to a 0.5 nmole to 0 nmole standard curve of MU in the presence of MUG (Figure 30). A unit is
defined as the conversion of one nmole of MUG to MU in one hour.
Results
The absorption scans indicated that there was a blue shift in the excitation wavelength of
the product from 362 nm at high pH to 321 nm at low pH. This result explains the decrease in
emission observed in the assay because the excitation peak was initially determined in high pH.
The substrate absorbs at 317 nm regardless of the pH, which means that at low pH both MU and
MUG are excited at the same wavelength, but with different molar extinction coefficients (Table
21), the spectra are displayed in Figures 32-33 (all spectra figures located in the appendix). Per
mole, MU absorbs approximately 1,000 fold more light in the 317-321 nm range than MUG,
however in an enzyme assay the substrate (MUG) is always in greater excess than the product
(MU), approximately 106 fold more. The results of the excitation scan are summarized in Table
22 and the spectra are located in Figures 34-35.
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Table 21. Absorption scan summary obtained from
the spectrophotometer

MUG/MU
MUG
MUG
MU
MU
MUG/MU
MUG/MU

pH
4.6
11
4.6
11
4.6
11

Wavelength
max
318
317
321
362
319
361

Molar extinction
coefficient (10-6)
0.015
0.022
14.3
10.9
0.029
0.022

Table 22. Excitation scan summary obtained from the Fluorometer

MUG/MU
MUG
MUG
MUG
MUG
MU
MU
MU
MU
MUG/MU
MUG/MU
MUG/MU
MUG/MU

pH
4.6
4.6
11
11
4.6
4.6
11
11
4.6
4.6
11
11

Emission
Wavelength
(nm)
380
445
380
445
380
445
380
445
380
445
380
445

Excitation
Wavelength
max
316
316
316
310
319
323
362
316
323
316
364

Molar
extinction
coefficient (106
)
177
8.95
68.8
3.46
88,618
1,118,380
1,504,280
166
21.4
76.1
19.0
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The maximum emission wavelength was independent of pH for both MU and MUG at
445 nm and 380 nm respectively, results displayed in Figures 36-37. A 40-fold increase in
intensity was observed in emission of MU in low pH when excited at 317 nm as opposed to 360
nm. At high pH there was only a 5-fold increase intensity when excited at 360 nm as opposed to
317 nm, all results summarized in Table 23. This data indicates that at low pH the MU molecule
is more sensitive to wavelength than at high pH. The proportion of emission intensity to
concentration of MU at low and high pH at their respective excitation optimums is comparable;
indicating that the decrease of emission observed previously in the continuous assay is likely due
to the wrong excitation wavelength.
The units calculated in the continuous assay excited at 315 nm is the same as the time
point assay at 360 nm and both were 4-fold higher than the continuous assay excited at 360 nm.
The results are summarized in Table 24. In order to determine the kinetic parameters of α-Gal a
substrate saturation curve using this method was developed. It was observed in this assay that
MUG inhibits the emission of MU in a concentration dependent manner, observed in Figure 30.
This result is likely explained by the inner filter effect (61), because MUG is in extreme excess
(2 mM versus 0.2 nM) and absorbs light at the same wavelength.
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In order to overcome this effect, the assay was done in 100 µL as opposed to 300 µL
which would fill up the well, and each substrate concentration was compared to a standard curve
containing the same concentration of MUG resulting in five standard curves for five
concentrations of MUG. This process allowed for the successful determination of Km, Vmax, and
Kcat of α-Gal as seen in the previous section.
Table 23. Fluorometer Emission Scan Summary

MUG/MU
MUG
MUG
MUG
MUG
MU
MU
MU
MU
MUG/MU
MUG/MU
MUG/MU
MUG/MU

pH
4.6
4.6
11
11
4.6
4.6
11
11
4.6
4.6
11
11

Excitation
Wavelength
(nm)
317
360
317
360
317
360
317
360
317
360
317
360

Emission
Wavelength
max
378
374
377
444
445
443
447
445
377
374
379
449

Molar
emission
coefficient
(10^-6)
175
0.55
67.6
0.49
1,094,480
26,504
285,980
1,475,560
163
0.6
80.4
18.6
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Table 24. Comparison of assays
Continuous Assay

Exact Enzyme Assay

Ex 360nm Em 465nm

Ex 315nm Em 450nm Ex 360nm Em 465nm

Gain Setting

Manual 50

Optimized 76

Optimized 39

Units/mL

601

2,582

2,610

0.5 nmole MU in Varying [MUG]
50000

FU

40000
30000
20000
10000
0

0

0.5

1

1.5

2

2.5

[MUG] (mM)

Figure 30. Fluorescence detection of MU in Varying MUG concentration.
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Discussion
The pKa value for MU is between 7 and 8 and previously it was reported that only the
deprotonated species was fluorescent (62). The structure of the protonated form is displayed in
Figure 31. Fluorophores are typically observed in aromatic molecules due to conjugation
observed in the delocalized pi electrons. From first principles, the protonation in no way
changes the aromaticity of the molecule so it should remain fluorescent. It has been previously
reported that the excitation wavelength for deprotonated phenols is red shifted or larger than their
protonated counter parts(63). Our results are consistent with this previous finding, although MU
is not a phenol it requires higher energy light to excite the protonated species.
The identification of the blue shift of the
excitation wavelength maximum of MU in low pH from
360 nm to 320 nm allows or a much more precise and
more automated assay to determine the activity of αFigure 31. Structure of MU from
Sigma Aldrich catalog

Gal. This discovery enables the construction of an
accurate continuous assay that can be compared to the

time point assay that is currently widely used in literature. There has been a previous report of
this blue shift finding of the excitation MU and the development of a continuous cuvette assay,
however this has only been utilized in plant science and requires much larger volumes(64).
The applications of this assay expand past laboratory research on α-Gal, because MU is a
fluorophore used as the product of many artificial substrates for enzymes involved with other
lysosomal storage disorders. A list of these disorders and the substrates that are used to analyze
them is located in Table 25. This technology can therefore be adapted to quickly screen for any
one of those disorders in conjunction with the already developed dried blood spot technique (65).
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Currently, infants are screened for phenylketonuria(66) and Pompe disease(67) at birth which
has drastically increased positive patient outcomes. This method can be utilized as a cost
effective method to screen infants at birth for these genetic disorders in order to provide the best
care for these patients as soon as possible and greatly improve the quality of their care.

87

Table 25. Methylumbelliferone (MU) based enzyme assays for lysosomal storage disorders.
Substrate
MU-α-D-galactoside
MU-β-D-lactopyranoside

Enzyme
Human α-galactosidase A
β-Galactosidase

MU α-D-mannopyranoside
MU-palmitate

Lysosomal acid αglucosidase
Acid lipase

MU-β-D-mannopyranoside

β-Mannosidase

MU-β-D-galactopyranoside-6sulfate
MU-6-thiopalmitoyl-β-Dglucoside

Galactose-6-sulphate
sulphatase
Palmitoyl protein
thioesterase-1

MU-β-D-glucopyranoside
MU-α-D-glucopyranoside
MU-2-acetamido-2-deoxy-βD-glucopyranoside
4-Methyl-MU-Gal-6-S

Glucocerebrosidase
Human lysosomal αglucosidase
Human lysosomal βhexosaminidase A
Arylsulfatase B

MU-α-L-iduronide

α-L-Iduronidase

MU-sulfate

Arylsulfatase

MU-β-D-glucuronide

β-Glucuronidase (Human)

MU-2-acetamido-2-deoxy-3,
4,6-tri-O-acetyl-β-Dglucopyranoside
MU-6-sulfo-2-acetamido-2deoxy-β-D glucopyranoside
MU-α-D-N-acetylneuraminate
6-Hexadecanoylamino-MUphosphorylcholine
MU-2-acetamide-2-deoxy-αD-galactopyranoside
MU-sulfate

Hyaluronidase

N-Acetylglucosamine I phosphotransferase
Sialidase
Sphingomyelinase
α-NAcetylgalactosaminidase
Iduronate-2-sulfatase

Disease/Application
Fabry disease
GM1-gangliosidosis,
Morquio disease type B
Glycogenosis type II
(Pompe disease)
Lysosomal acid
lipase (Wolman disease)
Carbohydrate-deficient
glycoprotein syndrome
type I
Morquio disease type A

Ref
(68)
(69)

Infantile neuronal ceroid
lipofuscinosis (Batten
Disease)
Gaucher disease
Pompe disease

(74)

Tay-Sachs disease

(77)

Mucopolysaccharidose
type VI
Mucopolysaccharidosis
type I (Hurler, Schelie
syndromes)
Maroteaux-Lamy
syndrome (MPS VI)
Mucopolysaccharidosis VII
(Sly syndrome)
Mucopolysaccharidosis
type IX (Natowicz
syndrome)
Mucolipidosis II and III

(78)

Mucolipidosis I
Nieman-Pick A and B

(84)
(85)

Schindler disease

(86)

Mucopolysaccharidosis
type II (Hunter Syndrome)

(87)

(70)
(71)
(72)

(73)

(75)
(76)

(79)

(80)
(81)
(82)

(83)
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Chapter 5 Conclusions and Future Studies
The need for an improved therapy for Fabry disease is significant. The only currently
available treatment is ERT, of which only Fabrazyme (Genzyme) is FDA approved. However,
both Fabrazyme and Replagal (Shire) are available worldwide. Both of these therapeutics result
in severe immune responses and are produced in mammalian cell lines making them extremely
expensive. There are clinical trials underway for additional ERTs such as moss-agal produced
by Greenovation Biopharmaceuticals and pegunigalsidase alfa produced by Protalix. Moss-agal is
produced in moss, which results in mannose terminated glycosylation, same as P. pastoris, and has
shown improvement in uptake in disease relevant cells (14). Pegunigalsidase alfa is produced in
tobacco, which also is mannose terminated, is chemically crosslinked with polyethylene glycol and
has shown to be more stable and have an increased half-life in plasma (25).
In addition to ERT, molecular chaperones such as Migalastat produced by Amicus
Therapeutics, are in late stage clinical trials and may be approved soon. The benefits to
chaperone therapy are the ability to treat tissues that are unable to take up current ERTs such as
the kidneys and brain, however the drawback is chaperone treatment only works for specific
mutations in the GLA gene (26). Substrate reduction therapy such as Ibiglustat also produced
by Genzyme, is another treatment currently in clinical trials. Both Ibiglustat and Migalastat are
small molecules and not a biologic; Ibiglustat inhibits the production of Gb3 (27) while Migalastat
increases the clearance of Gb3 like ERT. Earlier this year a patient was treated with gene therapy
for Fabry disease, which has been explored in the past (29).
The goal of this research is to develop a possible candidate for ERT for Fabry disease. This
goal was investigated in two methods: the production of functional α-Gal in a more economical
host such as E. coli or P. pastoris; and the use of protein engineering to construct a more
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functional enzyme. Initial work was done to produce a functional human α-Gal in E. coli.
However, despite many different manipulation methods such as mutations to allow disulfide bonds
to form and integration of an additional plasmid that coded for the production of tRNAs more
commonly used in humans, E. coli was unable to produce an active enzyme (Chapter 2). Prior to
this research’s work, active α-Gal was successfully produced from P. pastoris in this lab (32, 53).
This work set out to modify key areas for potential improvement to the enzyme using the known
crystal structure (2), catalytic mechanism (1), and bioinformatics techniques such as primary
sequence alignment and homology modeling. The three locations targeted for mutagenesis were
the active site, the dimer interface, and the hydrophobic loop between the active site and the third
glycosylation site.
Throughout the course of this investigation 22 mutations were introduced into the cDNA of
human α-Gal, of which 20 were integrated and expressed in P. pastoris (Chapter 3). Of the twenty
expressed mutants, eleven were cultured in shake flasks and the purification and characterization of
eight was successful. Of that eight, only three (W277C, Y207W, and E203C/Y207W) and one
additional derivation of another mutant (M208E) were selected for production in the bioreactor.
Two of these candidates, M208E and W277C, increase the catalytic efficiency of the enzyme.
M208E increases kcat/K0.5 3-fold, while retaining comparable stability to the wild type. W277C
increases kcat/K0.5 2-fold, while retaining comparable if not improved stability to the wild type, and
demonstrates an observed structural change on a native PAGE and a significantly positive
cooperative binding phenomena. Y207W may prove to also increase catalysis when an improved
purification method has been developed (Chapter 3). To better evaluate the kinetics of all the
mutants investigated, an improved continuous enzyme assay was developed, which in addition to
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being a very useful laboratory technique has potential to have clinical applications for screening of
lysosomal storage disorders (Chapter 4).
The future directions of this research include the further characterization of the W277C,
M208E, and Y207W mutants. The sigmoidal substrate saturation curve of particularly, W277C
should be further investigated, and should include exploration into the potential activation at the
secondary binding site as well as a crystal structure to identify the structural change to the enzyme.
The catalytic mechanism of M208E could be further examined to identify the locations of the
deviations between this mutant and the wild type. An optimized purification procedure for Y207W
should be developed, and from there investigation into the kinetics again. Another mutation worth
constructing is a glycosylation intact F211X to determine if the increase in catalysis could be
conserved while retaining the stability as was shown with M208E.
In addition to continued biochemical characterization, M208E and W277C should be
investigated for cellular uptake in endothelial cells. Another modification to consider is the
integration of these mutations into a humanized P. pastoris strain which would amend the
glycosylation to render the protein less immunogenic than the current stain (88). In the event that
these experiments prove successful, a Fabry mouse (89) or rat (90) study would be the next logical
step. If extensive preclinical research proves successful, these mutants could potential enter
clinical trials and hopefully become effective therapeutics for patients.
The continuous assay should be further studied in a clinical setting. If it proves to be useful
for Fabry disease, it should be readapted for any or all of the disorders listed in table 25 (Chapter
4). If this technique can be applied in a clinical setting, it could greatly decrease the cost of testing
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for these genetic disorders, so much so that it could be feasible to screen infants at birth to identify
the disease as early as possible for the best potential outcome in patient care.
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Appendix
Table 26. Non-linear Regression
Location
of
Mutation

N/A

Exact
Continuous
ex360nm

Km
(mM)
2.09
0.668
±0.026

Vmax
(mmol/hr/
mg)
0.019
0.028 ±
0.0004

kcat
(1/s)
0.46
0.71 ±
0.01

kcat/
Km
(1/sM)
221
1,064
± 25

Continuous
ex315nm

1.10
±0.06

0.067 ±
0.0029

1.68 ±
0.07

1,525
± 30

1

Continuous
ex360nm

0.56 ±
0.04

0.018 ±
0.0008

0.45 ±
0.02

794 ±
23

0.746

Continuous
ex315nm

0.66 ±
0.01

0.016 ±
0.0006

0.39 ±
0.02

595 ±
31

0.390

F273C

Continuous
ex315nm

2.70 ±
0.76

0.008 ±
0.0018

0.20 ±
0.04

76 ± 6

0.050

F273G/
W277G

Continuous
ex315nm

3.21 ±
0.68

0.013 ±
0.0021

0.33 ±
0.05

103 ±
5

0.068

Continuous
ex360nm

0.98 ±
0.17

0.017 ±
0.0016

0.42 ±
0.04

432 ±
34

0.406

Continuous
ex315nm

1.68 ±
0.25

0.041 ±
0.0048

1.01 ±
0.12

604 ±
17

0.399

Continuous
ex360nm

0.64 ±
0.004

0.079 ±
0.0015

1.97 ±
0.04

3,080
± 157

2.89

Continuous
ex315nm

0.62 ±
.08

0.177 ±
0.0077

2.93 ±
0.19

4,748
± 281

3.11

Continuous
ex315nm

1.02 ±
0.11

0.045 ±
0.0017

1.12 ±
0.04

1,097
± 72

0.84

Assay
Mutation

WT

W277C
Interface

E203C

Active
Site

Y207W

E203C/
Y207W

Glycosylation

Relative
kcat/Km
to WT
1

Sample
Contents

1

M208E/
N215Q

Continuous
ex360nm

0.46 ±
0.05

0.11 ±
0.0015

2.75 ±
0.04

5,984
± 582

5.62

F211X/
N215Q

Continuous
ex315nm

0.98 ±
0.12

0.207 ±
0.0123

5.18 ±
0.31

5,331
± 360

3.50

M208E/
F211H/
N215Q

Continuous
ex315nm

1.51 ±
0.62

0.045 ±
0.0147

1.12 ±
0.32

756 ±
55

0.50

N215Q

Continuous
ex315nm

1.28 ±
0.15

0.019 ±
0.0011

0.48 ±
0.03

380 ±
22

0.25

Concentrated
Thiogal
pool

Concentrated SP
pool *not
pure/
unstable
Concentrated
Thiogal
pool

Concentrated SP
pool

Concentrated
Thiogal
pool

Concentrated SP
pool
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Table 27. Lineweaver-Burke

Assay

Km
(mM)

Exact

9.3

Vmax
kcat
(mmol/hr/
(1/s)
mg)
0.067
1.67

Continuous
ex360nm

0.66 ±
0.07

0.028 ±
0.0014

0.69 ±
0.04

1,056 ±
83

Continuous
ex315nm

1.64 ±
0.06

0.086 ±
0.0021

2.14 ±
0.05

1,305 ±
13

1

Continuous
ex360nm

0.69 ±
0.11

0.019 ±
0.0013

0.48 ±
0.03

702 ± 76

0.665

Continuous
ex315nm

1.05 ±
0.009

0.020 ±
0.0018

0.5 ±
0.04

482 ± 10

0.369

F273C

Continuous
ex315nm

2.13 ±
0.38

0.007 ±
0.0010

0.17 ±
0.02

79 ± 3

0.061

F273G/
W277G

Continuous
ex315nm

11.9 ±
6.22

0.042 ±
0.0196

1.04 ±
0.49

89 ± 4

0.068

Continuous
ex360nm

0.48 ±
0.03

0.012 ±
0.0007

0.29 ±
0.02

616 ± 82

0.583

Continuous
ex315nm

2.54 ±
0.27

0.053 ±
0.0046

1.33 ±
0.12

524 ± 17

0.402

Continuous
ex360nm

0.47 ±
0.06

0.071 ± 0

1.79 ±
0

3,869 ±
270

3.66

Continuous
ex315nm

1.03 ±
0.05

0.155 ±
0.0034

3.88 ±
0.08

3,774 ±
93

2.89

Continuous
ex315nm

1.48 ±
0.10

0.057 ±
0.0045

1.42 ±
0.11

961 ± 48

0.74

Location Mutation

N/A

WT

W277C
Interface

E203C

Active
Site

Y207W

E203C/
Y207W

Glycosylation

kcat/Km
(1/sM)
179

Relative
kcat/Km
to WT
1
1

M208E/
N215Q

Continuous
ex360nm

0.33 ±
0

0.091 ± 0

2.29 ±
0

6,860 ± 0

6.50

F211X/
N215Q
M208E/
F211H/
N215Q

Continuous
ex315nm

1.14 ±
0.12

0.228 ±
0.0172

5.70 ±
0.43

5,004 ±
177

3.83

Continuous
ex315nm

1.07 ±
0.08

0.035 ±
0.0025

0.88 ±
0.06

829 ± 12

0.64

Continuous
ex315nm

3.96 ±
1.77

0.047 ±
0.0183

1.17 ±
0.46

299 ± 15

0.23

N215Q

Sample
Contents

Concentrated
Thiogal
pool

Concentrated SP
pool *not
pure/
unstable
Concentrated
Thiogal
pool

Concentrated SP
pool

Concentrated
Thiogal
pool

Concentrated SP
pool
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a)

b)

c)

Figure 32. Absorption spectra for MUG (a), MU (b), and MUG/MU (c) at pH 4.6
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a)

b)

c)
Figure 33. Absorption spectra for MUG (a), MU (b), and MUG/MU (c) at pH 11
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Figure 34. Excitation scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11
(bottom) emission 380 nm.
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Figure 35. Excitation scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11
(bottom) emission 445 nm.
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Figure 36. Emission scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11 (bottom)
excitation 317 nm.
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Figure 37. Emission scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11
(bottom) excitation 360 nm.
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